<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Allopurinol for chronic gout - Seth, R - 2014 | Cochrane Library</title> <meta content="Allopurinol for chronic gout - Seth, R - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006077.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Allopurinol for chronic gout - Seth, R - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006077.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006077.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Allopurinol for chronic gout" name="citation_title"/> <meta content="Rakhi Seth" name="citation_author"/> <meta content="University Hospital Southampton NHS Foundation Trust" name="citation_author_institution"/> <meta content="rs1299@doctors.org.uk" name="citation_author_email"/> <meta content="Alison SR Kydd" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Rachelle Buchbinder" name="citation_author"/> <meta content="Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University" name="citation_author_institution"/> <meta content="Claire Bombardier" name="citation_author"/> <meta content="Institute for Work &amp; Health" name="citation_author_institution"/> <meta content="Christopher J Edwards" name="citation_author"/> <meta content="University Hospital Southampton NHS Foundation Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD006077.pub3" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/10/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006077.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006077.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006077.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Allopurinol [*administration &amp; dosage]; Benzbromarone [administration &amp; dosage]; Chronic Disease; Colchicine [administration &amp; dosage]; Febuxostat; Gout [blood, *drug therapy]; Gout Suppressants [*administration &amp; dosage]; Probenecid [administration &amp; dosage]; Randomized Controlled Trials as Topic; Thiazoles [administration &amp; dosage]; Uric Acid [blood]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006077.pub3&amp;doi=10.1002/14651858.CD006077.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="IYhCEbRn";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006077\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006077\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006077.pub3",title:"Allopurinol for chronic gout",firstPublishedDate:"Oct 14, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006077.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006077.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006077.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006077.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006077.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006077.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006077.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006077.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006077.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006077.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11439 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006077.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/appendices#CD006077-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/table_n/CD006077StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/table_n/CD006077StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Allopurinol for chronic gout</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/information#CD006077-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Rakhi Seth</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/information#CD006077-cr-0003">Alison SR Kydd</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/information#CD006077-cr-0004">Rachelle Buchbinder</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/information#CD006077-cr-0005">Claire Bombardier</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006077.pub3/information#CD006077-cr-0006">Christopher J Edwards</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/information/en#CD006077-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 October 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006077.pub3">https://doi.org/10.1002/14651858.CD006077.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006077-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006077-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006077-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006077-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006077-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006077-abs-0001" lang="en"> <section id="CD006077-sec-0001"> <h3 class="title" id="CD006077-sec-0001">Background</h3> <p>Allopurinol, a xanthine oxidase inhibitor, is considered one of the most effective urate‐lowering drugs and is frequently used in the treatment of chronic gout. </p> </section> <section id="CD006077-sec-0002"> <h3 class="title" id="CD006077-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of allopurinol compared with placebo and other urate‐lowering therapies for treating chronic gout. </p> </section> <section id="CD006077-sec-0003"> <h3 class="title" id="CD006077-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE on 14 January 2014. We also handsearched the 2011 to 2012 American College of Rheumatology (ACR) and European League against Rheumatism (EULAR) abstracts, trial registers and regulatory agency drug safety databases. </p> </section> <section id="CD006077-sec-0004"> <h3 class="title" id="CD006077-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) or quasi‐randomised controlled clinical trials (CCTs) that compared allopurinol with a placebo or an active therapy in adults with chronic gout. </p> </section> <section id="CD006077-sec-0005"> <h3 class="title" id="CD006077-sec-0005">Data collection and analysis</h3> <p>We extracted and analysed data using standard methods for Cochrane reviews. The major outcomes of interest were frequency of acute gout attacks, serum urate normalisation, pain, function, tophus regression, study participant withdrawal due to adverse events (AE) and serious adverse events (SAE). We assessed the quality of the body of evidence for these outcomes using the GRADE approach. </p> </section> <section id="CD006077-sec-0006"> <h3 class="title" id="CD006077-sec-0006">Main results</h3> <p>We included 11 trials (4531 participants) that compared allopurinol (various doses) with placebo (two trials); febuxostat (four trials); benzbromarone (two trials); colchicine (one trial); probenecid (one trial); continuous versus intermittent allopurinol (one trial) and different doses of allopurinol (one trial). Only one trial was at low risk of bias in all domains. We deemed allopurinol versus placebo the main comparison, and allopurinol versus febuxostat and versus benzbromarone as the most clinically relevant active comparisons and restricted reporting to these comparisons here. </p> <p>Moderate‐quality evidence from one trial (57 participants) indicated allopurinol 300 mg daily probably does not reduce the rate of gout attacks (2/26 with allopurinol versus 3/25 with placebo; risk ratio (RR) 0.64, 95% confidence interval (CI) 0.12 to 3.52) but increases the proportion of participants achieving a target serum urate over 30 days (25/26 with allopurinol versus 0/25 with placebo, RR 49.11, 95% CI 3.15 to 765.58; number needed to treat for an additional beneficial outcome (NNTB) 1). In two studies (453 participants), there was no significant increase in withdrawals due to AE (6% with allopurinol versus 4% with placebo, RR 1.36, 95% CI 0.61 to 3.08) or SAE (2% with allopurinol versus 1% with placebo, RR 1.93, 95% CI 0.48 to 7.80). One trial reported no difference in pain reduction or tophus regression, but did not report outcome data or measures of variance sufficiently and we could not calculate the differences between groups. Neither trial reported function. </p> <p>Low‐quality evidence from three trials (1136 participants) indicated there may be no difference in the incidence of acute gout attacks with allopurinol up to 300 mg daily versus febuxostat 80 mg daily over eight to 24 weeks (21% with allopurinol versus 23% with febuxostat, RR 0.89, 95% CI 0.71 to 1.1); however more participants may achieve target serum urate level (four trials; 2618 participants) with febuxostat 80 mg daily versus allopurinol 300 mg daily (38% with allopurinol versus 70% with febuxostat, RR 0.56, 95% CI 0.48 to 0.65, NNTB with febuxostat 4). Two trials reported no difference in tophus regression between allopurinol and febuxostat over a 28‐ to 52‐week period; but as the trialists did not provide variance, we could not calculate the mean difference between groups. The trials did not report pain reduction or function. Moderate‐quality evidence from pooled data from three trials (2555 participants) comparing allopurinol up to 300 mg daily versus febuxostat 80 mg daily indicated no difference in the number of withdrawals due to AE (7% with allopurinol versus 8% with febuxostat, RR 0.89, 95% CI 0.62 to 1.26) or SAE (4% with allopurinol versus 4% with febuxostat, RR 1.13, 95% CI 0.71 to 1.82) over a 24‐ to 52‐week period. </p> <p>Low‐quality evidence from one trial (65 participants) indicated there may be no difference in the incidence of acute gout attacks with allopurinol up to 600 mg daily compared with benzbromarone up to 200 mg daily over a four‐month period (0/30 with allopurinol versus 1/25 with benzbromarone, RR 0.28, 95% CI 0.01 to 6.58). Based on the pooled results of two trials (102 participants), there was moderate‐quality evidence of no probable difference in the proportion of participants achieving a target serum urate level with allopurinol versus benzbromarone (58% with allopurinol versus 74% with benzbromarone, RR 0.79, 95% CI 0.56 to 1.11). Low‐quality evidence from two studies indicated there may be no difference in the number of participants who withdrew due to AE with allopurinol versus benzbromarone over a four‐ to nine‐month period (6% with allopurinol versus 7% with benzbromarone, pooled RR 0.80, 95% CI 0.18 to 3.58). There were no SAEs. They did not report tophi regression, pain and function. </p> <p>All other comparisons were supported by small, single studies only, limiting conclusions.</p> </section> <section id="CD006077-sec-0007"> <h3 class="title" id="CD006077-sec-0007">Authors' conclusions</h3> <p>Our review found low‐ to moderate‐quality evidence indicating similar effects on withdrawals due to AEs and SAEs and incidence of acute gout attacks when allopurinol (100 to 600 mg daily) was compared with placebo, benzbromarone (100 to 200 mg daily) or febuxostat (80 mg daily). There was moderate‐quality evidence of little or no difference in the proportion of participants achieving target serum urate when allopurinol was compared with benzbromarone. However, allopurinol seemed more successful than placebo and may be less successful than febuxostat (80 mg daily) in achieving a target serum urate level (6 mg/dL or less; 0.36 mmol/L or less) based on moderate‐ to low‐quality evidence. Single studies reported no difference in pain reduction when allopurinol (300 mg daily) was compared with placebo over 10 days, and no difference in tophus regression when allopurinol (200 to 300 mg daily) was compared with febuxostat (80 mg daily). None of the trials reported on function, health‐related quality of life or participant global assessment of treatment success, where further research would be useful. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006077-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006077-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006077-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006077-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006077-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006077-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006077-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006077-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006077-abs-0003" lang="en"> <h3>Allopurinol for chronic gout</h3> <p><b>Research question</b> </p> <p>This summary of a Cochrane review presents what we know from research about the effect of allopurinol compared with placebo or other treatments that reduce uric acid levels in treating people with chronic gout. The review is current to January 2014. </p> <p><b>Background: what is chronic gout and what is allopurinol?</b> </p> <p>Chronic gout is a common type of inflammatory arthritis caused by high levels of uric acid in the blood leading to crystal formation in the joints. Allopurinol is a medication that helps to lower blood uric acid levels. </p> <p><b>Study characteristics</b> </p> <p>After searching for all relevant studies, we found 11 studies that included 4531 adults with chronic gout. Two studies compared various doses of allopurinol (ranging from 100 to 300 mg daily) with placebo; four compared allopurinol with febuxostat; two compared allopurinol with benzbromarone; and one study each compared allopurinol with colchicine or probenecid. Two studies compared different treatment doses or administration methods of allopurinol. We considered allopurinol compared with placebo as the main comparison, and present results fully below. </p> <p><b>Key results</b> </p> <p><b>Allopurinol 100 to 300 mg daily versus placebo</b> </p> <p>Acute gout attacks </p> <p>‐ 4 fewer people out of 100 had an acute gout attack with allopurinol 100 to 300 mg daily compared with placebo <b>(</b>4% absolute reduction). </p> <p>‐ 8 people out of 100 had an acute gout attack with allopurinol.</p> <p>‐ 12 people out of 100 had an acute gout attack with placebo.</p> <p>Proportion of participants achieving target serum urate </p> <p>‐ 96 more people out of 100 achieved the target serum urate level with allopurinol (96% absolute increase). </p> <p>‐ 96 people out of 100 achieved target serum urate with allopurinol.</p> <p>‐ 0 people out of 100 achieved target serum urate with placebo.</p> <p>Withdrawal due to adverse events </p> <p>‐ 2 more people out of 100 had a withdrawal due to an adverse event with allopurinol (2% absolute increase). </p> <p>‐ 6 people out of 100 had a withdrawal due to an adverse event with allopurinol.</p> <p>‐ 4 people out of 100 had a withdrawal due to an adverse event with placebo.</p> <p>Serious adverse events </p> <p>‐ 1 more person out of 100 had a serious adverse event with allopurinol (1% absolute increase). </p> <p>‐ 2 people out of 100 had a serious adverse event with allopurinol.</p> <p>‐ 1 person out of 100 had a serious adverse event with placebo.</p> <p>Pain, function and tophus regression were not reported in sufficient detail to present results. </p> <p><b>Quality of the evidence</b> </p> <p>In people with chronic gout, moderate‐quality evidence indicated that, compared with placebo, allopurinol (100 to 300 mg daily) probably does not reduce the number of acute gout attacks, but does increase the proportion achieving target serum urate levels, without increasing withdrawals due to AEs or serious adverse event rates. Further research may change the estimates. Pain and tophus regression were not reported sufficiently to calculate group differences. Function was not measured. </p> <p>In people with chronic gout, compared with febuxostat (80 mg daily), low‐quality evidence indicated that allopurinol (100 to 300 mg daily) may not reduce the number of acute gout attacks, and may be less effective in achieving target serum urate levels, without increasing withdrawals due to AEs, or serious adverse event rates. Further research is likely to change the estimates. Tophus regression was not reported sufficiently to calculate group differences. Pain and function were not measured. </p> <p>In people with chronic gout, compared with benzbromarone (up to 200 mg daily), allopurinol (up to 600 mg daily) may not reduce the number of acute gout attacks (low‐quality evidence), probably does not increase the proportion achieving target serum urate levels, or the withdrawals due to AEs or serious adverse event rates (moderate‐quality evidence). Further research may change the estimates. Tophus regression was not reported sufficiently to calculate group differences and pain and function were not measured. </p> <p>The evidence was downgraded due to limitations in study design indicating potential bias, and possible imprecision. All other comparisons were supported by small, single studies only, limiting conclusions. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006077-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006077-sec-0090"></div> <h3 class="title" id="CD006077-sec-0091">Implications for practice</h3> <section id="CD006077-sec-0091"> <p>Allopurinol is widely considered a safe and effective urate‐lowering therapy used to treat chronic gout. However, our review highlights the relatively limited availability of high‐quality randomised controlled trial (RCT) evidence to support this view. </p> <p>Chronic gout results from the deposition of monosodium urate (uric acid crystals) from supersaturated body fluids and its manifestations include arthritis, tophi, uric acid urolithiasis and nephropathy. Urate‐lowering therapy reduces serum urate concentrations to subsaturating levels preventing the formation and deposition of urate crystals and consequently reduces the long‐term manifestations of chronic gout. However, the initiation of urate‐lowering therapy has been associated with an increased incidence of acute gout attacks and, therefore, flare prophylaxis (with non‐steroidal anti‐inflammatory drugs or colchicine) during this period is recommended. </p> <p>Allopurinol 300 mg daily probably does not reduce the incidence of acute gout attacks when compared with placebo over 30 days, and allopurinol 100 to 600 mg daily may not reduce acute gout attacks compared with benzbromarone 100 to 200 mg daily or febuxostat 80 mg daily over 16 to 24 weeks. While this review shows there may be similar effects when allopurinol was compared with benzbromarone for serum urate normalisation (moderate‐quality evidence), it does provide moderate‐quality evidence from one trial (57 participants) that allopurinol is probably more effective than placebo, and low‐quality evidence based on four studies (2618 participants) that allopurinol 100 to 300 mg daily may be less effective than febuxostat 80 mg daily in achieving a target serum urate level at 24 to 52 weeks. Single studies reported no difference in pain reduction when allopurinol 300 mg daily was compared with placebo over 10 days, and no difference in tophus regression when allopurinol 200 to 300 mg daily was compared with febuxostat 80 mg daily. None of the trials reported on other outcomes of interest including function, health‐related quality of life or participant global assessment of treatment success, where further research would be useful for clinical practice. </p> <p>Our review found low‐ to moderate‐quality evidence indicating similar effects on withdrawals due to adverse events or serious adverse events when allopurinol 100 to 600 mg daily was compared with placebo, benzbromarone 100 to 200 mg daily or febuxostat 80 mg daily. We did not identify any major new concerns regarding safety of allopurinol based on alerts from regulatory bodies. The most common adverse reaction with allopurinol was reported to be skin rash. </p> <p>We downgraded the evidence due to limitations in study design indicating potential bias, and possible imprecision. </p> <p>All other comparisons (allopurinol versus colchicine, allopurinol versus probenecid, continuous versus intermittent allopurinol and different doses of allopurinol) were supported by small, single studies only, limiting conclusions. </p> </section> <h3 class="title" id="CD006077-sec-0092">Implications for research</h3> <section id="CD006077-sec-0092"> <p>Due to the paucity of high‐quality RCT evidence comparing allopurinol initiation during an acute attack of gout with delayed initiation and potentially significant cost implications in changing our current practice, future trials assessing this would be beneficial for clinical practice. Future trials of allopurinol versus other urate‐lowering drugs should report on the method of randomisation and treatment allocation concealment, blinding of study participants, study personnel and outcome assessment, follow‐up of all participants who entered the trial and complete reporting of outcomes. To enable comparison and pooling of the results of RCTs, we suggest that future trials report means with SDs for continuous measures and number of events and total numbers analysed for dichotomous measures, and assess outcomes recommended by OMERACT (Outcome Measures in Rheumatology) for studies of acute gout, including pain, joint swelling, joint tenderness, participant global assessment and activity limitations (<a href="./references#CD006077-bbs2-0071" title="SchumacherHR , TaylorW , EdwardsL , GraingerR , SchlesingerN , DalbethN , et al. Outcomes domains for studies of acute and chronic gout. Journal of Rheumatology2009;36(10):2342‐5. ">Schumacher 2009</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006077-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006077-sec-0022"></div> <div class="table" id="CD006077-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Allopurinol compared with placebo for chronic gout</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Allopurinol compared with placebo for chronic gout</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with chronic gout<br/> <b>Settings:</b> primary care<br/> <b>Intervention:</b> allopurinol 100‐300 mg daily<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Allopurinol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute gout attacks</b> <br/> Follow‐up: 1‐30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> <br/> (14 to 422) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.64</b> <br/> (0.12 to 3.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute reduction in attacks with allopurinol: 4% (21% reduction to 12% increase)</p> <p>Relative change: 36% reduction with allopurinol (88% reduction to 252% increase)</p> <p>NNTB n/a<sup>2</sup> </p> <p>This study used allopurinol 300 mg daily (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion achieving target serum urate</b> <br/> Follow‐up: 1‐30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>960 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>960 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 49.11</b> <br/> (3.15 to 765.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference in proportion achieving target serum urate with allopurinol: 96% (86% to 106% increase) </p> <p>Relative change: 48% increase with allopurinol (215% to 76,458% increase)</p> <p>NNT 1 (95% CI 1.04 to 1.35)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain reduction</b> <br/> Follow‐up: 10 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors reported no difference in pain: the initial mean VAS pain scores for the allopurinol and placebo groups were 6.72 versus 6.28 (P value = 0.37) decreasing to 0.18 versus 0.27 (P value = 0.54) at day 10. No measures of variance reported, so we could not calculate the differences between groups<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tophus regression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal due to adverse events</b> <br/> Follow‐up: 0‐28 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>60 per 1000</b> <br/> (26 to 136) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.36</b> <br/> (0.61 to 3.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>453<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk difference in withdrawals due to adverse events with allopurinol: 2% increase (3% reduction to 6% increase) </p> <p>Relative change: 37% increase with allopurinol (39% reduction to 209% increase)</p> <p>NNT n/a<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> <br/> Follow‐up: 0‐28 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>24 per 1000</b> <br/> (6 to 98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.93</b> <br/> (0.48 to 7.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>453<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk difference in serious adverse events with allopurinol: 1% increase (1% reduction to 4% increase) </p> <p>Relative change: 93% increase with allopurinol (52% reduction to 676% increase)</p> <p>NNT n/a<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> One study with a small sample size, and wide CIs, indicating imprecision (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). </p> <p><sup>2</sup> Number needed to treat for an additional beneficial outcome (NNTB) or harmful outcome (NNTH) not applicable (n/a) when result was not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (<a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx/</a>).<br/> <sup>3</sup> Data from two studies were pooled for withdrawal due to adverse events and serious adverse events, the earlier trial is at unclear risk of selection, performance and detection bias, and the more recent trial is at low risk of bias (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008;</a><a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>).<br/> <sup>4</sup> One study reported on pain reduction, and is at low risk of bias, and had a small sample size (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006077-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Allopurinol 100‐300 mg daily compared with febuxostat 80 mg daily for chronic gout</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Allopurinol 100‐300 mg daily compared with febuxostat 80 mg daily for chronic gout</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with chronic gout<br/> <b>Settings: p</b> rimary and secondary care<br/> <b>Intervention:</b> allopurinol 100‐300 mg daily<br/> <b>Comparison: f</b>ebuxostat 80 mg daily </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Febuxostat 80 mg daily</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Allopurinol 100‐300 mg daily</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute gout attacks</b> <br/> Follow‐up: up to 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>233 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>207 per 1000</b> <br/> (165 to 256) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> <br/> (0.71 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1136<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute reduction in attacks with allopurinol: 2% (7% reduction to 3% increase)</p> <p>Relative change: 11% reduction with allopurinol (29% reduction to 10% increase)</p> <p>Not statistically significant. NNT n/a<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion achieving target serum urate</b> <br/> Follow‐up: 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>697 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>383 per 1000</b> <br/> (335 to 439) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.56</b> <br/> (0.48 to 0.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2618<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference in proportion achieving target serum urate with allopurinol: 32% fewer with allopurinol (40% fewer to 25% fewer) </p> <p>Relative change: 45% fewer with allopurinol (52% reduction to 37% reduction).</p> <p>NNTH 4 (95% CI 3 to 5)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain reduction</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tophus regression</b> <br/> Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no between‐group difference in the percentage reduction in tophus area at 52 weeks with 50% for participants taking allopurinol 200 or 300 mg daily and 83% for participants taking febuxostat 80 mg daily (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal due to adverse effects</b> <br/> Follow‐up: 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>68 per 1000</b> <br/> (48 to 97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.89</b> <br/> (0.62 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2555<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk difference in withdrawals due to adverse events with allopurinol: 1% reduction with allopurinol (3% reduction to 1% increase) </p> <p>Relative change: 11% reduction with allopurinol (38% reduction to 26% increase).</p> <p>Not statistically significant. NNT n/a<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse effects</b> <br/> Follow‐up: 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>39 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>44 per 1000</b> <br/> (28 to 71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.13</b> <br/> (0.71 to 1.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2556<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk difference in serious adverse events with allopurinol: 0% (2% reduction to 3% increase) </p> <p>Relative change: 13% increase with allopurinol (29% reduction to 82% increase)</p> <p>Not statistically significant. NNT n/a<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Two studies were at unclear risk (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and one study was at high risk (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), of performance and detection bias.<br/> <sup>2</sup> One study was at high risk of attrition bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>), one at unclear risk of attrition bias (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), and one at low risk of attrition bias (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>).<br/> <sup>3</sup> Three studies were at unclear risk (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and one study at high risk of performance and detection bias (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), and one trial at high risk of attrition bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>), whereas one was at unclear risk of attrition bias (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), and the other two studies were at low risk of attrition bias (<a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>, <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>).<br/> <sup>4</sup> Three studies used low‐dose allopurinol (100 to 300 mg daily depending on renal function) (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>).<br/> <sup>5</sup> Three studies were at unclear risk of reporting bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). </p> <p><sup>6</sup> Number needed to treat for an additional beneficial outcome (NNTB) or harmful outcome (NNTH) not applicable (n/a) when result was not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (<a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx/</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006077-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Allopurinol compared with benzbromarone for people with chronic gout</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Allopurinol compared with benzbromarone for people with chronic gout</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with chronic gout<br/> <b>Settings:</b> primary and secondary care<br/> <b>Intervention:</b> allopurinol 100‐600 mg daily<br/> <b>Comparison:</b> benzbromarone 100‐200 mg daily </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Benzbromarone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Allopurinol </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute gout attacks</b> <br/> Follow‐up: mean 4 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> <br/> (0 to 263) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.28</b> <br/> (0.01 to 6.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute reduction in attacks with allopurinol: 4% (14% reduction to 6% increase)</p> <p>Relative change: 72% reduction with allopurinol (99% reduction to 558% increase)</p> <p>Not statistically significant. NNT n/a<sup>4</sup> </p> <p>This study used allopurinol 100‐600 mg daily (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion achieving target serum urate</b> <br/> Follow‐up: 4‐9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>739 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>584 per 1000</b> <br/> (414 to 820) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> <br/> (0.56 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference in proportion achieving target serum urate with allopurinol: 17% reduction with allopurinol (45% reduction to 10% increase) </p> <p>Relative change: 21% reduction with allopurinol (44% reduction to 11% increase)</p> <p>Not statistically significant. NNT n/a<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain reduction</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tophus regression</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported in 1 study (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>), while the other study reported that 18/20 participants were cleared of tophi at 24 months but the authors do not provide further data for analysis) (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal due to adverse events</b> <br/> Follow‐up: median 4‐9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>57 per 1000</b> <br/> (13 to 256) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.80</b> <br/> (0.18 to 3.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk difference in withdrawals due to adverse events with allopurinol: 1% increase with allopurinol (10% reduction to 11% increase) </p> <p>Relative change: 20% reduction with allopurinol (82% reduction to 258% increase)</p> <p>Not statistically significant. NNT n/a<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse effects</b> <br/> Follow‐up: 4‐9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No adverse effects were considered serious" in the trial by <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a> and 1 participant died of cardiac failure after entering the <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a> trial, and the cause of death was thought unrelated to the study medication (which was not specified) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Small study (65 participants) (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>). Few events resulting in wide confidence interval.<br/> <sup>2</sup> Open‐label study with possible performance and detection bias and unclear risk related to possible attrition bias (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>).<br/> <sup>3</sup> Open‐label studies with possible performance bias and unclear risk related to possible attrition bias (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>). </p> <p><sup>4</sup> Number needed to treat for an additional beneficial outcome (NNTB) or harmful outcome (NNTH) not applicable (n/a) when result is not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (<a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx/</a>). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006077-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006077-sec-0023"></div> <section id="CD006077-sec-0024"> <h3 class="title" id="CD006077-sec-0024">Description of the condition</h3> <p>Gout is the most common inflammatory arthritis in men over the age of 40 years, and has increasing prevalence among postmenopausal women (<a href="./references#CD006077-bbs2-0052" title="ChohanS , BeckerMA . Update on emerging urate lowering therapies. Current Opinion in Rheumatology2009;21(2):143‐9. ">Chohan 2009</a>). It results from the deposition of monosodium urate (MSU) crystals in and around joints and soft tissues (<a href="./references#CD006077-bbs2-0069" title="SchlesingerN . Management of acute and chronic gouty arthritis. Drugs2004;64(21):2399‐416. ">Schlesinger 2004</a>). Formation of uric acid crystals requires hyperuricaemia defined as serum urate concentration above its solubility limit (6.8 mg/dL (0.41 mmol/L)) supersaturating the body fluids (<a href="./references#CD006077-bbs2-0070" title="SchumacherHR , EdwardsLN , Perez‐RuizF , BeckerM , ChenLX , FurstD , et al. Outcome measures for acute and chronic gout. Proceedings of OMERACT 7; 2004 May 8‐12; Asilomar (CA). ">Schumacher 2004</a>). </p> <p>Gout can evolve from asymptomatic hyperuricaemia to acute gout, which is characterised by the rapid onset of severe pain, swelling and redness of the affected joint. The period between attacks when the person is asymptomatic is referred to as inter‐critical gout. The final stage is chronic gout, characterised by the formation of tophi, which are nodular masses of MSU crystals deposited in the soft tissues of the body that can contribute to joint damage (<a href="./references#CD006077-bbs2-0067" title="KlippelJH , DieppePA , BrooksP , CaretteS , DequekerJ , GerberLH , et al. Rheumatology. London: Mosby, 1994. ">Klippel 1994</a>). Furthermore, hyperuricaemia can be associated with renal damage secondary to interstitial MSU crystal deposition and the formation of renal stones (<a href="./references#CD006077-bbs2-0069" title="SchlesingerN . Management of acute and chronic gouty arthritis. Drugs2004;64(21):2399‐416. ">Schlesinger 2004</a>). </p> <p>The treatment of acute gout attacks is aimed at controlling the inflammatory response and alleviating pain, and the drugs commonly used for this are non‐steroidal anti‐inflammatory drugs (NSAIDs), colchicine and glucocorticoids (<a href="./references#CD006077-bbs2-0078" title="WortmannRL . Gout and hyperuricaemia. Current Opinion in Rheumatology2002;14(3):281‐6. ">Wortmann 2002</a>). </p> </section> <section id="CD006077-sec-0025"> <h3 class="title" id="CD006077-sec-0025">Description of the intervention</h3> <p>As elevated serum uric acid (sUA) concentration is the most important determinant for the risk of developing gout (<a href="./references#CD006077-bbs2-0067" title="KlippelJH , DieppePA , BrooksP , CaretteS , DequekerJ , GerberLH , et al. Rheumatology. London: Mosby, 1994. ">Klippel 1994</a>), treatment is aimed at reducing hyperuricaemia. This prevents gouty attacks and the sequelae of long‐standing hyperuricaemia, such as chronic tophaceous gout and uric acid stones (<a href="./references#CD006077-bbs2-0069" title="SchlesingerN . Management of acute and chronic gouty arthritis. Drugs2004;64(21):2399‐416. ">Schlesinger 2004</a>). Maintaining the sUA level below saturating levels at a target of 6 mg/dL or less (or 0.36 mmol/L or less) is important in the treatment of chronic gout to reduce or reverse clinical events (<a href="./references#CD006077-bbs2-0064" title="JordanKM , CameronJS , SnaithM , ZhangW , DohertyM , SecklJ . British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology2007;46(8):1372‐4. ">Jordan 2007</a>). The urate‐lowing drugs available to treat chronic gout are: </p> <p> <ol id="CD006077-list-0001"> <li> <p>uricostatic drugs, which reduce urate production such as xanthine oxidase (XO) inhibitors, including allopurinol and febuxostat; </p> </li> <li> <p>uricosuric drugs, which increase urate excretion, including probenecid, benzbromarone and sulphinpyrazone; </p> </li> <li> <p>recombinant uricases, which catalyse the oxidation of uric acid to allantoin thereby lowering sUA, such as pegloticase and rasburicase (allantoin is an inert, water‐soluble purine metabolite, which is readily eliminated, primarily by renal excretion). </p> </li> </ol> </p> <p>Allopurinol is considered first‐line therapy for prevention of gout. The initial recommended dose of allopurinol is up to 100 mg daily, with a lower dose of 50 mg daily suggested in stage 4 or worse chronic kidney disease. The dose of allopurinol can be gradually titrated upwards every two to five weeks to an appropriate maximum dose in order to achieve a serum urate level target at a minimum of 6 mg/dL or less, which is the serum saturation point to prevent crystal formation, and may be lowered to 5 mg/dL (0.3 mmol/L) in some people with gout. The dosage of allopurinol can be raised above 300 mg daily, even in people with renal impairment, provided that the person receives adequate education and monitoring for drug toxicity (including measurement of transaminase levels). The maximum dosage of allopurinol approved by the US Food and Drug Administration (FDA) is 800 mg daily, but the maximum dosage should be lower in people with chronic kidney disease (<a href="./references#CD006077-bbs2-0066" title="KhannaD , FitzgeraldJD , KhannaPP , BaeS , SinghMK , NeogiT , et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Research2012;64(10):1431‐46. ">Khanna 2012</a>). </p> </section> <section id="CD006077-sec-0026"> <h3 class="title" id="CD006077-sec-0026">How the intervention might work</h3> <p>Allopurinol is a uricostatic drug that limits the production of uric acid. It is an isomer of hypoxanthine, which inhibits XO, thereby preventing the conversion of hypoxanthine to xanthine and xanthine to uric acid (<a href="./references#CD006077-bbs2-0077" title="WallaceSL , SingerJZ . Therapy in gout. Rheumatic Diseases Clinics of North America1988;14(2):441‐57. ">Wallace 1988</a>). This helps prevent uric acid crystal accumulation in the joints and tissues, thereby preventing attacks of gout and the sequelae of long‐standing hyperuricaemia, such as chronic tophaceous gout and uric acid stones. </p> </section> <section id="CD006077-sec-0027"> <h3 class="title" id="CD006077-sec-0027">Why it is important to do this review</h3> <p>Allopurinol is one of the most effective urate‐lowering drugs for gout and is frequently used. However, about 2% of people develop hypersensitivity reactions (<a href="./references#CD006077-bbs2-0053" title="DalbethN , StampL . Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Seminars in Dialysis2007;20(5):391‐5. ">Dalbeth 2007</a>), and 20% of those are severe, including rash, toxic epidermal necrolysis, hepatitis, interstitial nephritis and death (<a href="./references#CD006077-bbs2-0078" title="WortmannRL . Gout and hyperuricaemia. Current Opinion in Rheumatology2002;14(3):281‐6. ">Wortmann 2002</a>). Therefore, it is clinically relevant to review the benefit and safety of allopurinol for the treatment of chronic gout systematically. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006077-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006077-sec-0028"></div> <p>To assess the efficacy and safety of allopurinol compared with placebo and other urate‐lowering therapies for treating chronic gout. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006077-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006077-sec-0029"></div> <section id="CD006077-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006077-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included all randomised controlled trials (RCTs) or quasi‐randomised controlled clinical trials (CCTs) comparing allopurinol with another therapy (placebo, no treatment or other urate‐lowering treatment) in adults with chronic gout. </p> <p>We considered only trials that were published as full articles or were available as a full trial report. </p> </section> <section id="CD006077-sec-0032"> <h4 class="title">Types of participants</h4> <p>We considered trials that included adults (aged greater than 18 years) with a diagnosis of chronic gout. The diagnosis of gout could have been based on the American College of Rheumatology (ACR) criteria as outlined below or based on the diagnosis by the trial author or the treating physician. </p> <p>The ACR preliminary criteria for the classification of acute arthritis of primary gout remain the most frequently used criteria for chronic gout diagnosis in clinical trials (<a href="./references#CD006077-bbs2-0076" title="WallaceSL , RobinsonH , MasiAT , DeckerJL , McCartyDJ , YuTF . Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis and Rheumatism1977;20:895‐900. ">Wallace 1977</a>). According to these criteria, a person can be classified as having gout if MSU crystals are identified in a synovial fluid sample or tophus aspirate, or any of six out of 12 criteria are fulfilled following clinical, radiographic and laboratory. </p> <p> <ol id="CD006077-list-0002"> <li> <p>More than one attack of acute arthritis.</p> </li> <li> <p>Maximum inflammation developed within one day.</p> </li> <li> <p>Monoarthritis attack.</p> </li> <li> <p>Redness observed over joints.</p> </li> <li> <p>First metatarsophalangeal joint painful or swollen.</p> </li> <li> <p>Unilateral first metatarsophalangeal joint attack.</p> </li> <li> <p>Unilateral tarsal joint attack.</p> </li> <li> <p>Tophus (proved or suspected).</p> </li> <li> <p>Hyperuricaemia.</p> </li> <li> <p>Asymmetric swelling within a joint on x‐ray film.</p> </li> <li> <p>Subcortical cysts without erosions on x‐ray film.</p> </li> <li> <p>Joint culture negative for organism during attack.</p> </li> </ol> </p> <p>We excluded populations that included a mix of people with chronic gout and asymptomatic hyperuricaemia unless we could separate out results for the chronic gout population for analysis. </p> </section> <section id="CD006077-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We included all trials that evaluated allopurinol at any dose or dosing interval.</p> <p>Comparators could be any of the following:</p> <p> <ol id="CD006077-list-0003"> <li> <p>placebo;</p> </li> <li> <p>no treatment;</p> </li> <li> <p>another urate‐lowering therapy including febuxostat, probenecid, benzbromarone, sulphinpyrazone, pegloticase or rasburicase; </p> </li> <li> <p>one regimen of allopurinol versus another;</p> </li> <li> <p>a combination of urate‐lowering therapies.</p> </li> </ol> </p> </section> <section id="CD006077-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>The outcome measures were based on the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10) gout report recommended outcome domains for chronic gout (<a href="./references#CD006077-bbs2-0071" title="SchumacherHR , TaylorW , EdwardsL , GraingerR , SchlesingerN , DalbethN , et al. Outcomes domains for studies of acute and chronic gout. Journal of Rheumatology2009;36(10):2342‐5. ">Schumacher 2009</a>; <a href="./references#CD006077-bbs2-0074" title="SinghJA , TaylorWJ , SimonLS , KhannaPP , StampLK , McQueenFM , et al. Patient‐reported outcomes in chronic gout: a report from OMERACT 10. Journal of Rheumatology2011;38(7):1452‐7. ">Singh 2011</a>). </p> <section id="CD006077-sec-0035"> <h5 class="title">Major outcomes</h5> <p>We listed the following outcomes in the 'Summary of findings' tables:</p> <p> <ol id="CD006077-list-0004"> <li> <p>frequency of acute gout attacks and the number of participants with an acute gout attack was the preferred dichotomous outcome; </p> </li> <li> <p>serum urate normalisation as measured by per cent change in uric acid from baseline, absolute change in uric acid from baseline (mmol/L or mg/dL) or proportion of participants achieving a target serum urate (e.g. less than 6 mg/dL (less than 0.36 mmol/L)) (the preferred outcome); </p> </li> <li> <p>pain (e.g. as measured on the visual analogue scale (VAS), numerical rating scale (NRS), Likert scales or qualitative scales); </p> </li> <li> <p>function (i.e. activity limitation) (e.g. as measured by the Health Assessment Questionnaire Disability Index (HAQ‐DI), 36‐item Short Form (SF‐36) Physical Health component or other validated gout specific function measures); </p> </li> <li> <p>tophus regression, using physical measurement techniques (e.g. Vernier callipers) or ultrasound‐guided measurements (<a href="./references#CD006077-bbs2-0054" title="DalbethN , SchauerC , MacDonaldP , Perez‐RuizF , SchumacherHR , HamburgerS . Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide. Annals of the Rheumatic Diseases2011;70(4):597‐604. ">Dalbeth 2011</a>); </p> </li> <li> <p>proportion of participant withdrawals due to AE;</p> </li> <li> <p>proportion of participants with serious adverse events (SAEs).</p> </li> </ol> </p> </section> <section id="CD006077-sec-0036"> <h5 class="title">Minor outcomes</h5> <p> <ol id="CD006077-list-0005"> <li> <p>Health‐related quality of life (HRQoL) (e.g. as described by SF‐36, Gout Assessment Questionnaire (GAQ) and the Gout Impact Scale (GIS) or other validated gout‐specific HRQoL measures (<a href="./references#CD006077-bbs2-0065" title="KhannaD , SarkinAJ , KhannaPP , ShiehMM , KavanaughA , TerkeltaubR , et al. Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology2011;50(7):1331‐6. ">Khanna 2011</a>); </p> </li> <li> <p>participant global assessment of treatment success;</p> </li> <li> <p>proportion of participants with AEs.</p> </li> </ol> </p> </section> </section> </section> <section id="CD006077-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006077-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases from inception:</p> <p> <ol id="CD006077-list-0006"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) 14 January 2014 (<a href="./appendices#CD006077-sec-0096">Appendix 1</a>); </p> </li> <li> <p>Ovid MEDLINE 1948 to 14 January 2014 (<a href="./appendices#CD006077-sec-0097">Appendix 2</a>); </p> </li> <li> <p>EMBASE 1980 to 14 January 2014 (<a href="./appendices#CD006077-sec-0098">Appendix 3</a>). </p> </li> </ol> </p> <p>We applied no language restrictions.</p> </section> <section id="CD006077-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We searched abstracts from the two major international rheumatology scientific meetings ‐ the ACR and the European League Against Rheumatism (EULAR) ‐ or the years 2011 and 2012, and the reference lists of included articles for additional trials. We searched trial registers including the ClinicalTrials.gov register (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>) and the World Health Organization (WHO) trial register (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>). </p> <p>For rare SAEs, we also searched black box warnings and regulatory agency sources:</p> <p> <ul id="CD006077-list-0007"> <li> <p>Medicine and Healthcare products Regulatory Agency (MHRA), 'Drug Safety Update' (<a href="http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/index.htm" target="_blank">www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/index.htm</a>); </p> </li> <li> <p>Australian Database of Adverse Event Notifications (<a href="http://www.tga.gov.au/safety/index.htm" target="_blank">www.tga.gov.au/safety/index.htm</a>); </p> </li> <li> <p>MedWatch: the FDA Safety Information and Adverse Event Reporting Program (US) ‐ Adverse Event Reporting System (<a href="http://www.fda.gov/Safety/MedWatch/default.htm" target="_blank">www.fda.gov/Safety/MedWatch/default.htm</a>); </p> </li> <li> <p>European Public Assessment Reports from the European Medicines Evaluation Agency (EMEA) (<a href="http://www.emea.europa.eu/" target="_blank">www.emea.europa.eu/</a>). </p> </li> </ul> </p> <p>We planned to describe any data obtained from these sources.</p> </section> </section> <section id="CD006077-sec-0040"> <h3 class="title" id="CD006077-sec-0040">Data collection and analysis</h3> <section id="CD006077-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Two review authors (RS and AK) independently reviewed the results of the search to identify trials that fulfilled our inclusion criteria. We reviewed titles and abstracts and, if more information was required to determine whether a trial met the inclusion criteria, we obtained the full text. We kept a record for the reasons for excluding studies and resolved any disagreements by discussion and with a third review author (RB). We planned to translate eligible studies to English if needed, but we identified no non‐English language studies for inclusion. </p> </section> <section id="CD006077-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (RS and AK) independently extracted relevant information from the included trials including study design, characteristics of study population, treatment regimen and duration, outcomes and timing of outcome assessment, using pre‐determined forms. We resolved differences in data extraction by referring back to the original articles and establishing consensus. A third review author (RB) acted as arbiter to help resolve differences if necessary. </p> <p>We extracted the raw data (means and standard deviations (SD) for continuous outcomes and the number of events for dichotomous outcomes) for outcomes of interest and entered relevant data into Review Manager 5 (<a href="./references#CD006077-bbs2-0068" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>). </p> </section> <section id="CD006077-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RS and AK) independently assessed risk of bias of all included studies using The Cochrane Collaboration's tool for assessing risk of bias (<a href="./references#CD006077-bbs2-0061" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). This included assessing the bias in each of the following domains: random sequence generation; allocation concealment; blinding of participants, personnel and outcome assessors; completeness of outcome data; selective reporting and other sources of bias (including whether there was carry‐over effect from previous therapies, whether appropriate co‐intervention (e.g. colchicine or NSAIDs) were administered and whether any pre‐administered interventions could have diminished the effect of the subsequent randomised intervention). </p> <p>We graded each of these criteria were graded as 'high risk' of bias, 'low risk' of bias or 'unclear risk' of bias. We resolved disagreements by consensus; if we could not reach a consensus, a third review author (RB) acted as arbiter. </p> </section> <section id="CD006077-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>We summarised the data in a meta‐analysis only if there was sufficient clinical homogeneity.</p> <p>For dichotomous data, we presented the results as risk ratios (RR) with corresponding 95% confidence intervals (CI). An RR greater than 1.0 indicated a beneficial effect of allopurinol. </p> <p>For continuous data, we presented the results as mean differences (MD) between the intervention and comparator groups with the corresponding 95% CIs. </p> <p>When different scales were used to measure the same conceptual domain, we planned to calculate the standardised mean differences (SMD) with corresponding 95% CIs instead. For the calculation of SMD, MD was divided by the SD, resulting in a unitless measure of treatment effect. SMDs larger than zero indicated a beneficial effect of allopurinol. An SMD of 0.2 indicated a small beneficial effect, 0.5 a medium effect and 0.8 a large effect in favour of allopurinol. We had planned to re‐express SMDs as MD by multiplying the SMD by a typical among‐person SD using a familiar scale in order to facilitate appraisal by clinicians (<a href="./references#CD006077-bbs2-0073" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>); however, we did not need to do this. </p> </section> <section id="CD006077-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We assessed whether each study evaluated the number of people with acute flares or the number of acute flares as a unit of analysis, and we evaluated the number of people with acute flares as the preferred outcome. </p> <p>We planned to avoid a potential unit of analysis issue by making multiple pair‐wise comparisons between all possible pairs of intervention groups for trials with multiple treatment groups, or alternatively, by including only the pair with accepted drug dosages (<a href="./references#CD006077-bbs2-0063" title="HigginsJPT , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011c</a>). </p> </section> <section id="CD006077-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>If data were missing or incomplete, we planned to obtain further information from the study authors, but this was not necessary. </p> <p>We had planned that in cases where individual data were missing from the reported results and no further information was available from the study authors, we would assume the missing values to have a poor outcome. For dichotomous variables that measured AEs, we would have calculated the withdrawal rate using the number of participants who received the treatment as the denominator (worst‐case analysis). For dichotomous outcomes that measured benefits, we would have calculated the worst‐case analysis using the number of randomised participants as the denominator. For continuous variables, we planned to calculate the MD or the SMD based on the number of participants analysed at each time point. If the number of participants analysed was not available, we would have used the number of randomised participants in each group at baseline. </p> <p>Where possible, we would have calculated missing SDs from other statistics such as standard errors, CIs or P values, according to methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006077-bbs2-0062" title="HigginsJPT , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). If we could not calculate SDs, we would have imputed them from other studies in the meta‐analysis (<a href="./references#CD006077-bbs2-0063" title="HigginsJPT , DeeksJJ , AltmanDG . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011c</a>). </p> </section> <section id="CD006077-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and statistical heterogeneity between studies.</p> <p>For clinical homogeneity, we determined whether or not the included studies were similar with respect to study participants, intervention groups, outcome measures and timing of outcome. </p> <p>For studies judged as clinically similar, we assessed statistical heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD006077-bbs2-0055" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). We used the following thresholds for the interpretation of the I<sup>2</sup> statistic: 0% to 40% heterogeneity might not be important, 30% to 60% represented moderate heterogeneity, 50% to 90% represented substantial heterogeneity and greater than 75% represented considerable heterogeneity. In cases of considerable heterogeneity, we planned to explore the data further, including subgroup analyses, in an attempt to explain heterogeneity. </p> </section> <section id="CD006077-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>To assess the potential for reporting bias, we determined whether the protocol of the trial was published before recruitment of participants began. For trials published after 1 July 2005, we screened the Clinical Trials Register at the International Clinical Trials Registry Platform of the World Health Organization (WHO) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). We evaluated whether selective reporting of outcomes was present. </p> <p>We planned to compare the fixed‐effect model estimate against the random‐effects model estimate to assess the possible presence of small‐sample bias in the published literature (i.e. in which the intervention effect was more beneficial in smaller studies). In the presence of small‐sample bias, the random‐effects estimate of the intervention was more beneficial than the fixed‐effect estimate (<a href="./references#CD006077-bbs2-0075" title="SterneJAC , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Sterne 2011</a>). </p> <p>We planned to explore the potential for small‐study effects in the main outcomes of the review using funnel plots if at least 10 studies were included in a meta‐analysis; however, this was not undertaken due to the lack of studies. </p> </section> <section id="CD006077-sec-0049"> <h4 class="title">Data synthesis</h4> <p>When we considered studies sufficiently homogenous in terms of the study population and interventions delivered, we pooled outcome data in a meta‐analysis using a random‐effects model, irrespective of the I<sup>2</sup> results (<a href="./references#CD006077-bbs2-0055" title="DeeksJJ , HigginsJPT , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD006077-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We hypothesised that responses to treatment may differ according to the participant's age and gender. Elderly participants can present with more associated conditions and possibly a greater chance of adverse effects (<a href="./references#CD006077-bbs2-0049" title="BusquetsN , CarmonaL , SurisX . Systematic review: safety and efficacy of anti‐TNF in elderly patients. Rheumatologica Clinica2011;7(2):104‐12. ">Busquets 2011</a>), while reports indicate that gout in women may have different epidemiological and clinical characteristics compared with gout in men (<a href="./references#CD006077-bbs2-0060" title="HarroldLR , YoodRA , MikulsTR , AndradeSE , DavisJ , FullerJ , et al. Sex differences in gout epidemiology: evaluation and treatment. Annals of the Rheumatic Diseases2006;65(10):1368‐72. ">Harrold 2006</a>). </p> <p>Therefore, we planned the following subgroup analyses if sufficient data were available:</p> <p> <ol id="CD006077-list-0008"> <li> <p>participant's age (65 years or greater or less than 65 years);</p> </li> <li> <p>gender (men versus women).</p> </li> </ol> </p> <p>We had planned to extract the outcome 'acute gout attacks' separately for men and women, and the outcome 'withdrawals due to adverse events' separately by age subgroups from within each trial. We also planned to compare the magnitudes of effect informally to assess possible differences in response to treatment by considering the overlap of the CIs of the summary estimates in the two subgroups with non‐overlap of the CIs indicating statistical significance. However, the outcomes were not reported by subgroups within the trials, thereby precluding the planned analyses. </p> </section> <section id="CD006077-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>Where sufficient studies existed, we planned sensitivity analyses to explore the impact of any bias attributable to lack of randomisation, inadequate or unclear allocation concealment and outcome assessor blinding. </p> <p>We also planned to assess the presence of small‐study bias (i.e. intervention effect was more beneficial in smaller studies) in the meta‐analysis by comparing the fixed‐effect estimate and the random‐effects estimate. </p> <p>We planned to investigate the effect of any missing or imputed data by sensitivity analysis. </p> <section id="CD006077-sec-0052"> <h5 class="title">Presentation of results</h5> <p>We presented the main results in 'Summary of findings' tables. These tables provide key information concerning the quality of evidence, the magnitude of effect of the interventions examined and the sum of available data on our seven main outcomes (participant‐reported reduction in acute gout attack frequency, proportion of participants achieving a target serum urate level, joint pain reduction, function, tophus regression, number of study participant withdrawals due to AEs and SAEs), as recommended by The Cochrane Collaboration (<a href="./references#CD006077-bbs2-0072" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>). It includes an overall grading of the evidence related to each of the main outcomes using the GRADE approach (<a href="./references#CD006077-bbs2-0073" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). </p> <p>The 'Summary of findings' tables show the three most clinically relevant comparisons, as deemed by the review authors (RS, AK, RB), including allopurinol versus placebo, allopurinol versus febuxostat and allopurinol versus benzbromarone. </p> <p>In the comments column, we calculated the absolute percentage change and the relative percentage change; and, for outcomes with statistically significant differences between intervention groups, we calculated the number needed to treat for an additional beneficial outcome (NNTB), or the number needed to treat for an additional harmful outcome (NNTH). </p> <p>For dichotomous outcomes, we calculated the absolute risk difference using the risk difference statistic in Review Manager 5 (<a href="./references#CD006077-bbs2-0068" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>), and expressed the result as a percentage; we calculated the relative percentage change as the RR ‐ 1 and expressed it as a percentage; and determined the NNT from the control group event rate and the RR using the Visual Rx NNT calculator (<a href="./references#CD006077-bbs2-0050" title="CatesC . Visual Rx Version 3. www.nntonline.net/visualrx (accessed 3 September 2014). ">Cates 2008</a>). </p> <p>For continuous outcomes, we would have calculated the absolute risk difference as the MD between intervention and control groups in the original measurement units (divided by the scale), expressed as a percentage; we would have calculated the relative difference as the absolute change (or MD) divided by the baseline mean of the control group from a representative trial; however, we did not need to do this. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006077-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006077-sec-0053"></div> <section id="CD006077-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD006077-sec-0055"> <h4 class="title">Results of the search</h4> <p>The literature search was originally performed on 17 February 2012 and updated on 6 August 2013 and 14 January 2014. It identified 3982 abstracts (see <a href="#CD006077-fig-0001">Figure 1</a>). After exclusion of 1266 duplicates, we screened 2716 abstracts and retrieved 46 articles for detailed review. From this, 11 trials met the inclusion criteria (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>; <a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>; <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>; <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>; <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). </p> <div class="figure" id="CD006077-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006077-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We found no additional trials from the search of abstracts from the 2011 and 2012 annual scientific meetings of ACR or EULAR or from the handsearch. </p> </section> <section id="CD006077-sec-0056"> <h4 class="title">Included studies</h4> <p>We provide a full description of the 11 included trials in the <a href="./references#CD006077-sec-0114" title="">Characteristics of included studies</a> table. </p> <section id="CD006077-sec-0057"> <h5 class="title">Design</h5> <p>There were seven RCTs (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>; <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>), and four CCTs (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>; <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>; <a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). Two trials (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), were combined into a three‐year open‐label extension study (<a href="./references#CD006077-bbs2-0048" title="BeckerMA , SchumacherHR , MacDonaldPA , LloydE , LademacherC . Clinical efficacy and safety of successful long term urate lowering with febuxostat or allopurinol in subjects with gout. Journal of Rheumatology2009;36(6):1273‐82. ">Becker 2009</a>), but we have not reported these data in this review. </p> </section> <section id="CD006077-sec-0058"> <h5 class="title">Participants</h5> <p>Five RCTs (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>), and two CCTs (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), defined their study population as having gout using the ARA criteria (<a href="./references#CD006077-bbs2-0076" title="WallaceSL , RobinsonH , MasiAT , DeckerJL , McCartyDJ , YuTF . Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis and Rheumatism1977;20:895‐900. ">Wallace 1977</a>), while the remaining four used an alternative definition. <a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a> defined their study population as having "at least one attack of acute arthritis associated with a raised blood uric acid unrelated to drugs or other diseases"; while <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a> defined their study population as having a "diagnosis of gout, confirmed by microscopic evidence of urate crystals from synovial fluid or periarticular structures or the presence of tophi". <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a> defined their study population as having "recurrent paroxysms of monoarticular inflammation characteristic of acute gouty arthritis, and all had hyperuricaemia", and <a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a> defined their study population as having gout which was "as far as could be determined, primary and uncomplicated except in some cases with minor degrees of renal functional impairment". </p> <p>Six trials specifically stated that their gout population were over the age of 18 years (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>; <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>), while five trials did not (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>; <a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>; <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). </p> <p>Three trials had an all male population (<a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>; <a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>; <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>), seven RCTs had a majority male population (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>; <a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>; <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and one trial did not define the gender of their study population with gout (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). The duration of gout affecting the participants was reported in all 11 studies, and ranged from a few days to 25 years. </p> <p>Five trials were set in the USA (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>), three in London, UK (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989;</a><a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982;</a><a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>), one in the Netherlands (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>), one in Spain (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>), and one in Bangladesh (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). </p> </section> <section id="CD006077-sec-0059"> <h5 class="title">Interventions</h5> <p>Two trials compared allopurinol with placebo (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). One of these investigated immediate versus delayed administration of allopurinol during an acute attack of gout and participants were randomised to allopurinol versus placebo for the first 10 days of the trial after which time all participants took allopurinol (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). One trial compared allopurinol plus colchicine with colchicine alone (<a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>). One trial compared allopurinol with probenecid (<a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>), and two trials compared allopurinol with benzbromarone (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>). Four trials compared allopurinol with febuxostat (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). In addition, one trial compared allopurinol 300 mg daily versus allopurinol 100 mg three times daily (<a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>), and one trial compared continuous versus two months per year of allopurinol (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>). </p> </section> <section id="CD006077-sec-0060"> <h5 class="title">Outcomes</h5> <p>All trials measured the number of acute attacks of gout, while all except one trial (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>) measured serum urate change or normalisation. Only one trial assessed joint pain (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). Four trials included a measure of tophus regression (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>). Safety as assessed by the number of study participant withdrawals due to AEs and SAEs was reported in all except one trial (<a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>). AEs were reported by all except two trials (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989;</a><a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>). SAEs were reported in eight trials and three trials did not report SAEs (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989;</a><a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982;</a><a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). None of the trials reported on function or HRQoL measures. </p> <section id="CD006077-sec-0061"> <h6 class="title">Allopurinol versus placebo</h6> <p><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a> performed a multicentre, three‐armed, double‐blind RCT (the Allopurinol and Placebo‐Controlled, Efficacy Study of Febuxostat (APEX) trial) including 1072 participants, with gout as per ARA criteria, and compared allopurinol 100 or 300 mg daily based on renal function with febuxostat 80, 120 or 240 mg daily or placebo. Additional medication included colchicine 0.6 mg once daily or naproxen 250 mg twice daily during the washout period for people receiving prior urate‐lowering therapies or on randomisation for people not on prior urate‐lowering therapy. These medications were continued for the first eight weeks of the study as prophylaxis for gout flares. The investigator used their own judgement in selecting between naproxen and colchicine, although colchicine was recommended for people with a serum creatinine level greater than 1.5 mg/dL. Study treatment was taken for 28 weeks and outcomes were assessed every four weeks. The primary efficacy end point was the proportion of participants with the last three monthly serum urate levels less than 6.0 mg/dL (less than 0.36 mmol/L). Overall, outcome assessments were made on three out of the seven essential domains proposed by OMERACT. The study end points were acute gout attack frequency, serum urate (both change in serum urate and serum urate less than 6 mg/dL) and tophus regression. Safety as assessed by the number of study participant withdrawals due to AEs and SAEs were also reported. </p> <p><a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a> performed a single‐centre, parallel arm, double‐blind, placebo‐controlled RCT including 57 participants presenting within seven days of onset of an acute attack of crystal‐confirmed gout and who met the ARA criteria and compared allopurinol 300 mg daily versus placebo for 10 days. After 10 days, participants in the placebo arm were also started on allopurinol 300 mg daily. Duration of the trial was 90 days (as colchicine was continued for 90 days) and outcomes were assessed at day one, three, 10 and 30 plus or minus three days to accommodate weekends or conflicts. All participants received additional medications including colchicine 0.6 mg twice daily for 90 days and indomethacin 50 mg three times daily for 10 days. Outcome assessments were made on three out of the seven essential domains proposed by OMERACT. The study end points were acute gout attack frequency, serum urate (both change in serum urate and proportion achieving a target serum urate less than 6 mg/dL) and pain (measured using a VAS). Safety as assessed by the number of study participant withdrawals due to AEs and SAEs were also reported. </p> </section> <section id="CD006077-sec-0062"> <h6 class="title">Allopurinol plus colchicine versus colchicine alone</h6> <p><a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a> performed a single‐centre RCT including 59 participants with gout that compared allopurinol 200 mg daily plus colchicine 0.5 mg twice daily with colchicine 0.5 mg twice daily alone. In an earlier paper, <a href="./references#CD006077-bbs2-0058" title="GibsonT , SimmondsHA , PotterC , RogersV . A controlled study of the effect of long term allopurinol treatment on renal function in gout. Advances in Experimental Medicine and Biology1980;122(A):257‐62. ">Gibson 1980</a> reported on the same trial but described 57 participants. <a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a> included participants with gout defined as having at least one attack of acute arthritis associated with a raised blood uric acid unrelated to drugs or other diseases, while <a href="./references#CD006077-bbs2-0058" title="GibsonT , SimmondsHA , PotterC , RogersV . A controlled study of the effect of long term allopurinol treatment on renal function in gout. Advances in Experimental Medicine and Biology1980;122(A):257‐62. ">Gibson 1980</a> referred to participants having primary gout of at least one year' duration. For the purpose of our review, we used data in <a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>. Duration of treatment was at least one year and 55 participants received treatment for two years. Outcomes were assessed every two to three months, then at 12 and 24 months and outcome assessments were made on two out of the seven essential domains proposed by OMERACT (acute gout attack frequency and serum urate level). Safety, as assessed by the number of study participant withdrawals due to AEs and SAEs, were not reported in this trial. </p> </section> <section id="CD006077-sec-0063"> <h6 class="title">Allopurinol versus probenecid</h6> <p><a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a> performed a single‐centre open quasi‐randomised CCT including 40 participants with gout (investigator defined) comparing allopurinol with a uricosuric (probenecid initially, then 5/17 on probenecid changed to sulphinpyrazone 400 mg daily due to "minor" adverse effects). Allopurinol was commenced at 300 mg daily and increased when necessary (authors did not defined how) up to 600 mg daily, and probenecid 1 g daily rising to 2 g/daily after two weeks. All participants also received colchicine 0.5 mg twice or three times daily and this was withdrawn "several months after the last attack of gout". The mean follow‐up was 18.6 months for allopurinol and 19.6 months for probenecid, and outcomes were assessed at initial assessment; two weeks; then one, two and three months and at three‐monthly intervals thereafter. Outcome assessments were made on three out of the seven essential domains proposed by OMERACT. The study end points were acute gout attack frequency, serum urate and tophus regression. Safety as assessed by the number of study participant withdrawals due to AEs were also reported, although SAEs were not reported. </p> </section> <section id="CD006077-sec-0064"> <h6 class="title">Allopurinol versus febuxostat</h6> <p><a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a> conducted a multicentre, 52‐week, three‐armed double‐blind RCT (the Febuxostat versus Allopurinol Controlled Trial (FACT) trial) including 762 participants with gout (as per ARA criteria) that compared allopurinol 300 mg daily with febuxostat 80 or 120 mg daily. All participants also received two months of acute gout prophylaxis with either colchicine 0.6 mg daily or naproxen 250 mg twice daily. The authors do not state how they decided who received colchicine and who received naproxen. Any subsequent attacks were treated according to the discretion of the investigators. Duration of treatment was 12 months and outcomes were assessed at two weeks, four weeks and then monthly for 12 months in total) and follow‐up extended for another month to assess AEs (13 months in total). Outcome assessments were made on three out of the seven essential domains proposed by OMERACT. The study end points included serum urate (both change in serum urate and serum urate less than 6 mg/dL), acute gout attack frequency and tophus regression. Safety as assessed by the number of study participant withdrawals due to AEs and SAEs were also reported. </p> <p><a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a> conducted a multicentre, two‐armed double‐blind RCT (the urate lowering efficacy and safety of febuxostat in the treatment of hyperuricaemia of gout (CONFIRMS) trial) including 2269 participants with gout (as per ARA criteria) that compared allopurinol 200 or 300 mg daily (depending on renal function) with febuxostat 40 or 80 mg daily, over six months and outcomes were assessed every two months for six months in total. Participants received acute gout prophylaxis with either colchicine or naproxen for the duration of the trial, and choice of prophylaxis was made by the investigator and participant, taking into account prior drug tolerance and prophylaxis experience. In addition, participants with an estimated creatinine clearance less than 50 mL/minute were not given naproxen. Outcome assessments were made on two out of the seven essential domains proposed by OMERACT. The study end points included serum urate (serum urate less than 6 mg/dL) and acute gout attack frequency. Safety as assessed by the number of study participant withdrawals due to AEs and SAEs were also reported. </p> <p><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a> performed a multicentre, three‐armed, double‐blind RCT (the APEX trial) including 1072 participants, with gout as per ARA criteria, and compared allopurinol 300 or 100 mg daily based on renal function with febuxostat 80, 120 or 240 mg daily or placebo. See 'Allopurinol versus placebo'. </p> <p><a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a> conducted a two‐armed non‐randomised CCT including 100 participants with gout (as per ARA criteria) that compared allopurinol 300 mg daily with febuxostat 80 mg daily, over six months and outcomes were assessed at two weeks and then at month four, five and six (final visit). Participants did not receive any acute gout prophylaxis. Outcome assessments were made on two out of the seven essential domains proposed by OMERACT. The study end points were serum urate (less than 6 mg/dL) and acute gout attack frequency. Safety as assessed by the number of study participant withdrawal due to AEs or SAEs were not reported, but AEs were reported. </p> </section> <section id="CD006077-sec-0065"> <h6 class="title">Allopurinol versus benzbromarone</h6> <p><a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a> performed a single‐centre open RCT in 37 participants with gout (as per ARA criteria) and renal impairment (calculated creatinine clearance 20 to 80 mL/minute/1.73m<sup>2</sup>) and compared allopurinol (100‐150 mg daily initially and then titrated up to 100 (according to creatinine clearance 20 to 40 mL/minute), 200 (according to creatinine clearance 40 to 60mL/minute) or 300 mg daily (according to creatinine clearance 60 to 80 mL/minute) versus benzbromarone (100 mg daily titrated up with increments of 50 to 200 mg daily). Participants in the allopurinol group could cross‐over to the benzbromarone group if they did not achieve target sUA level (less than 6 mg/dL) at maximum doses of allopurinol (corrected for creatinine clearance). The timing of the titration or cross‐over was not specified. Colchicine 0.5 to 1 mg daily was given for six months from the start of urate‐lowering therapy. If colchicine was not tolerated, NSAIDs were used. Duration of the study was nine to 12 months if serum urate less than 6 mg/dL was achieved and 12 to 24 months for participants who changed from allopurinol to benzbromarone or participants with tophi. Outcomes were assessed at nine, 12 and 24 months and assessments were made on three out of the seven essential domains proposed by OMERACT. The study end points were acute gout attack frequency, serum urate (both change in serum urate and serum urate less than 6 mg/dL) and tophus regression. Safety as assessed by the number of study participant withdrawals due to AEs and SAEs were also reported. </p> <p><a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a> performed a multicentre open RCT in 65 participants with gout (confirmed by microscopic evidence of urate crystals from synovial fluid or peri‐articular structures or the presence of tophi) to investigate the comparative efficacy and tolerability of dose escalation of allopurinol versus benzbromarone to attain a target serum urate of 5 mg/dL. Participants in the allopurinol group received a starting dose of 100 mg daily, which increased by 100 mg each week to 300 mg daily, while participants in the benzbromarone group initially received 100 mg daily. If the treatment was tolerated but the treatment goal of serum urate 0.30 mmol/L or less was not reached at two months, then the allopurinol dose was doubled to 300 mg twice daily and the benzbromarone dose to 200 mg daily. Additional medications included colchicine 0.5 to 1 mg daily until serum urate 0.30 mmol/L or less was reached. If colchicine was not tolerated, then NSAIDs were used. Duration of treatment was four months, and outcomes were assessed at two months (before dose escalation) (stage 1) and then at four months (after dose escalation) (stage 2). Outcome assessments were made on two out of the seven essential domains proposed by OMERACT. The study end points were acute gout attack frequency and serum urate (both change in serum urate and serum urate less than 6 mg/dL). Safety as assessed by the number of study participant withdrawals due to AEs and SAEs were also reported. </p> </section> <section id="CD006077-sec-0066"> <h6 class="title">Allopurinol: intermittent versus continuous</h6> <p><a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a> conducted a single‐centre, two‐armed "quasi‐randomised" CCT including 50 participants with gout (as per ARA criteria), which compared two different allopurinol regimens: continuous versus intermittent. Participants in the continuous group received allopurinol 100 mg daily for the first week, 200 mg daily for the second week and then were maintained continuously by a dose adequate to keep their sUA level less than 6 mg/dL for men; this dose was usually 300 mg daily. Participants in the intermittent group received allopurinol starting at 100 mg daily for the first week, then 200 mg daily for the second week and then 300 mg daily for six weeks. This protocol could only be performed once every 12 months. Both groups received NSAID for the first month of starting allopurinol, and, in the continuous group, participants with a history of duodenal ulceration were occasionally prescribed colchicine. Duration of treatment ranged from two to four years and outcome was assessed every three to four months. Outcome assessments were made on two out of the seven essential domains proposed by OMERACT. The primary study end points were acute gout attack frequency and serum urate (although no data on specific serum urate levels were presented). No adverse effects were reported. </p> </section> <section id="CD006077-sec-0067"> <h6 class="title">Allopurinol: split‐dose allopurinol versus once‐daily allopurinol</h6> <p><a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a> performed an open cross‐over trial (CCT) including 20 participants with gout defined by "recurrent paroxysms of monoarticular inflammation characteristic of acute gouty arthritis, and all had hyperuricaemia". All participants had a two‐week washout period during which no allopurinol or other medication known to affect sUA was given. Participants were then randomly allocated to receive either allopurinol 300 mg daily given in three divided doses of 100 mg (group A) or allopurinol 300 mg as a single dose (group B) for two weeks. All participants then had a second washout period of one week during which no allopurinol was given and then the alternate regimen of allopurinol was given for two weeks. Additional medications included colchicine (0.5 mg twice or three times daily) or indomethacin (25 mg twice daily to 50 mg three times daily) or both throughout the seven‐week trial. Outcomes were assessed weekly, and assessments were made on two out of the seven essential domains proposed by OMERACT. The study end points were acute gout attack frequency and serum urate (both change in serum urate and serum urate less than 6 mg/dL). Adverse effects were also reported. </p> </section> </section> </section> <section id="CD006077-sec-0068"> <h4 class="title">Excluded studies</h4> <p>We excluded 35 studies after review of the full text of potentially eligible articles. Of these exclusions, five were the wrong population, seven had no or the wrong comparator, one had the wrong outcome, 21 were the wrong study type and one study lacked hard data for extraction. </p> <p>The <a href="./references#CD006077-sec-0115" title="">Characteristics of excluded studies</a> table summarises the reasons for exclusion of the 35 excluded studies. </p> </section> </section> <section id="CD006077-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary assessment of the risk of bias is presented in the <a href="./references#CD006077-sec-0114" title="">Characteristics of included studies</a> table and <a href="#CD006077-fig-0002">Figure 2</a> and <a href="#CD006077-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD006077-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006077-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006077-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006077-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>Following risk of bias assessment, we found only <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a> to be at low risk of bias in all domains. We have summarised the risk of bias assessments for all studies below. </p> <section id="CD006077-sec-0070"> <h4 class="title">Allocation</h4> <p>Four trials described adequate random sequence generation and allocation concealment and we assessed them as being at low risk of selection bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>; <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). Two trials used a computer‐generated central randomisation schedule with block sizes of three to six to randomise participants (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>); one trial used an interactive voice response system to initiate double‐blind randomisation (<a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>), and one trial used a random number generator (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). Two trials had inadequate random sequence generation and we assessed them as being at unclear risk of bias (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and both had inadequate allocation concealment; we assessed <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a> as being at high risk of bias, and <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a> at unclear risk of bias. One trial described inadequate random sequence generation and allocation concealment and we assessed this as being at high risk of bias for random sequence generation and at unclear risk of bias for allocation concealment (<a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>). The remaining four trials were described as having inadequate random sequence generation and allocation concealment and we assessed them as being at high risk of selection bias (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>; <a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>; <a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). </p> </section> <section id="CD006077-sec-0071"> <h4 class="title">Blinding</h4> <p>Two trials described adequate blinding of both the participants and personnel (performance bias) and of outcome assessment (detection bias) and we assessed them as being at low risk of performance and detection bias (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989;</a><a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). Six trials described inadequate blinding of both the participants and personnel (performance bias) and of outcome assessment (detection bias) and we assessed them as being at unclear risk of performance and detection bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>). One trial described inadequate blinding of the participants and personnel (performance bias) and of outcome assessment (detection bias) and we assessed it as being at high risk of performance bias and unclear risk of detection bias (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>). Finally, two trials described inadequate blinding of both the participants and personnel (performance bias) and of outcome assessment (detection bias) and we assessed them as being at high risk of both performance and detection bias (<a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982;</a><a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). <a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a> did not describe the method of blinding and <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a> was a non‐randomised CCT. </p> </section> <section id="CD006077-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed three trials as low risk for attrition bias (<a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008;</a><a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a> did not include one participant out of 2268 in the efficacy analysis (as the sUA was less than 8 mg/dL (less than 0.48 mmol/L)), whereas the remainder were included in a modified intention‐to‐treat (ITT) analysis. <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a> reported that all efficacy analyses were performed on an ITT population and <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a> discussed all withdrawals. We assessed four trials at unclear risk for attrition bias (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989;</a><a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>; <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). <a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a> reported that four participants defaulted from follow‐up in the intermittent group and six defaulted in the control group. Four participants in the intermittent group went on to continuous treatment at their own request because of recurrent attacks of gout, and one participant in the intermittent group received an additional prescription of allopurinol. Two participants in the continuous group stopped taking allopurinol of their own volition but continued to be followed for three years in total. <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a> reported that 10 participants were excluded from analysis from the allopurinol group (six lost to follow‐up, three due to protocol violation and one not mentioned in results) while five participants were excluded from analysis from the benzbromarone group (four lost to follow‐up and one poor adherence). There was also an unclear risk of bias with respect to attrition given the number of participants who withdrew from <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>, as 15 out of 65 (23%) participants withdrew from the study, and the number of withdrawals were higher for allopurinol (10 participants) than benzbromarone (five participants) (not statistically significant) and similar reasons were given when comparing the two groups. <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a> did not report sufficient evidence regarding loss to follow‐up. <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a> did not report on loss to follow‐up, treatment withdrawals or major AEs. The remaining four trials had unexplained incomplete outcome data and we judged them as being at high risk of attrition bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982;</a><a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999;</a><a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>). </p> </section> <section id="CD006077-sec-0073"> <h4 class="title">Selective reporting</h4> <p>We assessed three trials as being at low risk for reporting bias (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>; <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). We assessed seven trials at unclear risk (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>; <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), and one trial at high risk for reporting bias as insufficient information was reported (<a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>). </p> </section> <section id="CD006077-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed other potential sources of bias including whether there was carry‐over effect from previous therapies, whether appropriate co‐intervention (e.g. colchicine or NSAIDs) were administered and whether any pre‐administered interventions could diminish the effect of the subsequent randomised intervention. We assessed six trials as being at low risk of other potential sources of bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>), and five at unclear risk of other sources of potential bias, such as carry‐over effect from previous therapies (<a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>; <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>; <a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). </p> </section> </section> <section id="CD006077-sec-0075"> <h3 class="title" id="CD006077-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD006077-tbl-0001"><b>Summary of findings for the main comparison</b> Allopurinol compared with placebo for chronic gout</a>; <a href="./full#CD006077-tbl-0002"><b>Summary of findings 2</b> Allopurinol 100‐300 mg daily compared with febuxostat 80 mg daily for chronic gout</a>; <a href="./full#CD006077-tbl-0003"><b>Summary of findings 3</b> Allopurinol compared with benzbromarone for people with chronic gout</a> </p> <section id="CD006077-sec-0076"> <h4 class="title">Allopurinol versus placebo</h4> <p>While the efficacy data from the two trials that compared allopurinol with placebo could not be pooled due to lack of clinical homogeneity with differences in trial design, they did report similar results, and we pooled the safety data from these two trials (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). </p> <p>One trial with 1072 participants, judged to be at unclear risk of bias, compared a dose of up to 300 mg of allopurinol (dependent on renal function) with placebo (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). There was no between‐group difference in the proportion of participants requiring treatment for gout flares in the first eight weeks of the trial (during the period of co‐administration of naproxen 250 mg twice daily or colchicine 0.6 mg daily) when allopurinol was compared with placebo (61/268 (23%) in allopurinol group versus 27/134 (20%) in placebo group, RR 1.13, 95% CI 0.76 to 1.69) (<a href="./references#CD006077-fig-0004" title="">Analysis 1.1</a>). The authors also reported no between‐group difference in gout flares between weeks eight and 28 although these data were not provided. </p> <p>The second trial with 57 participants, judged to be at low risk of bias, compared the initiation of allopurinol 300 mg during an acute attack of gout versus placebo for 10 days followed by allopurinol 300 mg daily (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). They reported no between‐group difference in the rate of new or recurrent gout attacks between days one and 30 when allopurinol was compared with 10 days of placebo and then allopurinol (2/26 (7.7%) in allopurinol group versus 3/25 (12%) in placebo group, RR 0.64, 95% CI 0.12 to 3.52) (<a href="./references#CD006077-fig-0004" title="">Analysis 1.1</a>). Both treatment groups also received colchicine for 90 days and indomethacin for 10 days from trial commencement. </p> <p><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a> reported that participants in the allopurinol group were more likely to achieve a target serum urate level less than 6.0 mg/dL (0.36 mmol/L) with the last three monthly serum urate measurements (103/263 in allopurinol group versus 1/127 in placebo group, RR 49.25, 95% CI 6.95 to 349.02) (<a href="./references#CD006077-fig-0005" title="">Analysis 1.2</a>). For the subgroup with impaired renal function, none of the participants in the allopurinol 100 mg daily group (1/10) or placebo group (0/5) achieved this target. <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a> reported that the serum urate levels decreased rapidly in the allopurinol group, reaching less than 6.5 mg/dL by day 10 for all but one of the participants while none of the 25 placebo group participants achieved this end point (25/26 in allopurinol group versus 0/25 in placebo group, RR 49.11, 95% CI 3.15 to 765.58) (<a href="./references#CD006077-fig-0005" title="">Analysis 1.2</a>), and the NNTB was 1 (95% CI 1.04 to 1.35). <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a> reported no between‐group differences with respect to pain reduction to day 10 (no measure of variance reported). <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a> reported no between‐group differences in number of tophi or tophus regression but did not provide the data. Neither trial provided data for function, participant global assessment of treatment success or quality of life. </p> <p>Pooled analysis showed no between‐group difference in the number of participants who withdrew due to AEs (19/294 in allopurinol group versus 7/159 in placebo group, RR 1.37, 95% CI 0.61 to 3.09) (<a href="./references#CD006077-fig-0006" title="">Analysis 1.3</a>), total AE (210/294 in allopurinol group versus 110/159 in placebo group, RR 1.00, 95% CI 0.89 to 1.14) (<a href="./references#CD006077-fig-0007" title="">Analysis 1.4</a>) or SAE (8/294 in allopurinol group versus 2/159 in placebo group, RR 1.93, 95% CI 0.48 to 7.80) (<a href="./references#CD006077-fig-0008" title="">Analysis 1.5</a>), when allopurinol was compared with placebo. </p> <p>The reasons for withdrawal in the allopurinol groups in both trials were abnormal liver function tests, diarrhoea and a gout attack less than 24 hours after starting allopurinol. An elevation in creatinine greater than 1.5 mg/dL occurred in one participant in each study arm in <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>. One participant died unexpectedly (after receiving four doses of allopurinol) from gastroenteritis, pneumonia, fever, dehydration and acute renal failure. The authors did not state whether or not they considered it related to the study medication (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). One participant initially in the placebo group had a hypersensitivity reaction with rash, fever and mild transaminitis leading to discontinuation of allopurinol at day 30 (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>), and we have excluded from the data analysis as both placebo and allopurinol were given to this participant. </p> </section> <section id="CD006077-sec-0077"> <h4 class="title">Allopurinol plus colchicine versus colchicine alone</h4> <p>One trial including 59 participants, judged to be at high risk of bias, compared allopurinol 200 mg daily plus colchicine 0.5 mg twice daily with colchicine 0.5 mg twice daily alone (<a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>). There was no between‐group difference in the number of gout attacks in the first year of treatment (recurrent attacks: 5/26 in allopurinol plus colchicine group versus 10/33 in colchicine alone group, RR 0.63, 95% CI 0.25 to 1.63) (<a href="./references#CD006077-fig-0009" title="">Analysis 2.1</a>). The mean serum urate level after two years was reported to be significantly lower in the allopurinol plus colchicine group (mean ± SD: 0.28 ± 0.07 in allopurinol plus colchicine group versus 0.37 ± 0.1 in colchicine only group, between‐group difference and variance not provided). Three participants in the allopurinol plus colchicine group were analysed in the colchicine group because they were non‐compliant with medication. No data for joint pain, function, quality of life, participant global assessment of treatment success, tophus regression or safety were provided. </p> </section> <section id="CD006077-sec-0078"> <h4 class="title">Allopurinol versus probenecid</h4> <p>One trial including 40 participants, judged to be at high risk of bias, compared allopurinol 300 to 600 mg daily with probenecid (1 g daily increasing to 2 g daily after two weeks) (<a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>). The trial authors did not provide any statistical analyses. From the data presented, there did not appear to be a between‐group difference in the number of gout attacks reported over the duration of the study (11/20 in allopurinol group versus 9/17 in probenecid group). Mean (range) serum urate was reported to decrease from 9.3 (7.5 to 10.6) mg/dL at baseline to 4.7 (2.6 to 5.5) mg/dL at the final end point in the allopurinol group and 8.5 (7.5 to 11.7) mg/dL at baseline to 5.2 (3.8 to 7.3) mg/dL at final end point in the probenecid group (no measures of variance were reported). Of those participants with tophi (five overall), disappearance of tophi occurred in two of three participants in the allopurinol group and one of two in the probenecid group. None of our other pre‐specified efficacy outcomes were reported, therefore we extracted no other outcomes. There did not appear to be any between‐group difference in number of adverse effects and no SAEs were reported in either group. </p> </section> <section id="CD006077-sec-0079"> <h4 class="title">Allopurinol versus febuxostat</h4> <p>Data from four trials, of which we considered three to be at unclear risk of bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and one at high risk of bias (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), were considered sufficiently clinically homogeneous to be pooled (number of participants: 762 with <a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>, 2269 with <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>, 1072 with <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>, 100 with <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). The allopurinol dose varied between 300 mg daily (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>) and either 100 to 300 mg (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), or 200 to 300 mg daily depending on renal function (<a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>). Febuxostat doses varied between 40 or 80 mg daily (<a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>); 80 or 120 mg daily (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>); 80, 120 or 240 mg daily (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>); or 80 mg daily (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). All participants in the three larger trials received acute gout prophylaxis during the first two months of treatment (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), whereas participants in the smaller trial did not receive any flare prophylaxis (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). </p> <p>Pooled analyses showed that there was no between‐group difference in the frequency of acute gout attacks when allopurinol up to 300 mg daily was compared with febuxostat 80 mg daily (118/569 in allopurinol group versus 132/567 in febuxostat 80 mg group, RR 0.89, 95% CI 0.71 to 1.10) (<a href="./references#CD006077-fig-0010" title="">Analysis 3.1</a>) based on three trials (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008;</a><a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). A sensitivity analysis excluding the non‐randomised CCT (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>) did not alter the results (113/519 in allopurinol group versus 128/517 in febuxostat 80 mg group, RR 0.88, 95% CI 0.70 to 1.09) (analysis not shown). Participants taking allopurinol had significantly fewer acute gout attacks compared with participants taking higher doses of febuxostat based on two trials (116/519 in allopurinol group versus 187/519 in febuxostat 120 mg group, RR 0.62, 95% CI 0.51 to 0.76) (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and based on one trial (61/268 in allopurinol group versus 69/134 in febuxostat 240 mg group, RR 0.44 95% CI 0.34 to 0.58) (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). </p> <p>Achievement of a target serum urate less than 6 mg/dL at final end point (six to 12 months) could be pooled for up to four trials depending on dose of febuxostat in the control group. One trial reported no difference between allopurinol 200 or 300 mg daily and febuxostat 40 mg daily at final end point (six months) (number achieving target serum urate: 318/755 in allopurinol group versus 342/757 in febuxostat 40 mg daily group, RR 0.93, 95% CI 0.83 to 1.05) (<a href="./references#CD006077-fig-0011" title="">Analysis 3.2</a>) (<a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>). Allopurinol was less likely to achieve the target serum urate when compared with higher doses of febuxostat: febuxostat 80 mg daily based on four trials (526/1310 in allopurinol group versus 912/1308 in febuxostat group, RR 0.55, 95% CI 0.48 to 0.63) (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>); febuxostat 120 mg daily based on two trials (190/505 in allopurinol group versus 402/507 in febuxostat group, RR 0.48, 95% CI 0.42 to 0.54) (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>); or febuxostat 240 mg daily based on one trial (102/263 in allopurinol group versus 116/126 in febuxostat group, RR 0.42, 95% CI 0.36 to 0.49) (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). </p> <p>A sensitivity analysis of achievement of target serum urate less than 6 mg/dL at final end point (six to 12 months) of allopurinol up to 300 mg daily versus febuxostat 80 mg daily excluding the non‐randomised CCT (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>) did not alter the results (508/1260 in allopurinol group versus 875/1258 in febuxostat group, RR 0.56, 95% CI 0.48 to 0.65) (data not shown). </p> <p>There were no between‐group difference in the percentage reduction in tophus area at final end point (12 months) with 50% for participants on allopurinol 200 or 300 mg daily, 83% for participants on febuxostat 80 mg daily and 66% for participants on febuxostat 120 mg daily (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>). There was no between‐group differences in the number of tophi, with the exception of a mean percentage reduction in the number of tophi occurring in participants on febuxostat 120 mg daily (‐1.2) compared with placebo (‐0.3) at the final end point (<a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>). </p> <p>Withdrawals due to adverse effects could be pooled for up to three trials depending on the dose of febuxostat in the control group. One trial reported no between‐group differences in withdrawals between allopurinol (200 or 300 mg daily) and febuxostat 40 mg daily (64/755 withdrawals in allopurinol group versus 49/757 in febuxostat 40 mg daily group, RR 1.31, 95% CI 0.92to 1.87) (<a href="./references#CD006077-fig-0012" title="">Analysis 3.3</a>) (<a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>). Based on three trials, there were no between‐group differences in withdrawals comparing allopurinol and febuxostat 80 mg daily (withdrawals: 90/1276 in allopurinol group versus 98/1279 in febuxostat 80 mg daily group, RR 0.89, 95% CI 0.62 to 1.26) (<a href="./references#CD006077-fig-0012" title="">Analysis 3.3</a>). Based on two trials, there were also no between‐group differences in withdrawals comparing allopurinol and febuxostat 120 mg daily (withdrawals: 36/521 in allopurinol group versus 42/520 in febuxostat 120 mg daily group, RR 0.85, 95% CI 0.56 to 1.31) (<a href="./references#CD006077-fig-0012" title="">Analysis 3.3</a>) (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and based on one trial, no between‐group differences in withdrawals comparing allopurinol and febuxostat 240 mg daily (withdrawals: 18/268 in allopurinol group versus 13/134 in febuxostat 240 mg daily group, RR 0.69, 95% CI 0.35 to 1.37) (<a href="./references#CD006077-fig-0012" title="">Analysis 3.3</a>) (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). Reasons for withdrawals due to AEs included abnormal liver function tests, diarrhoea, rashes, upper respiratory tract infections and musculoskeletal and connective tissue disease features (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a> did not report any withdrawals due to AE or SAE in either group. </p> <p>We could pool AEs for up to four trials depending on the dose of febuxostat in the control group. <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a> reported no between‐group differences in AE between allopurinol (200 or 300 mg daily) and febuxostat 40 mg daily (AEs: 433/756 in allopurinol group versus 429/757 in febuxostat 40 mg daily group, RR 1.01, 95% CI 0.93 to 1.10) (<a href="./references#CD006077-fig-0013" title="">Analysis 3.4</a>). Based on four trials, allopurinol resulted in more AEs than febuxostat 80 mg daily (AEs: 850/1327 in allopurinol group versus 802/1329 in febuxostat 80 mg daily group, RR 1.06, 95% CI 1.01 to 1.12) (<a href="./references#CD006077-fig-0013" title="">Analysis 3.4</a>) (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), and based on two trials, allopurinol also resulted in more AEs than febuxostat 120 mg daily (AEs: 415/516 in allopurinol group versus 372/520 in febuxostat 120 mg daily group, RR 1.12, 95% CI 1.05 to 1.20) (<a href="./references#CD006077-fig-0013" title="">Analysis 3.4</a>) (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a> reported no between‐group differences in AE between allopurinol and febuxostat 240 mg daily (AEs: 200/268 in allopurinol group versus 98/134 in febuxostat 240 mg daily group, RR 1.02, 95% CI 0.90 to 1.15) (<a href="./references#CD006077-fig-0013" title="">Analysis 3.4</a>). AEs included rashes and mild hypersensitivity, abnormal liver function tests, upper respiratory tract infections, peripheral oedema, musculoskeletal and connective tissue disease features, gastrointestinal (including nausea and diarrhoea) and neurological features (including headache). </p> <p>SAE could be pooled for up to three trials depending on the dose of febuxostat in the control group. <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a> reported no between‐group differences in SAE comparing allopurinol (200 or 300 mg daily) and febuxostat 40 mg daily (SAEs: 31/756 in allopurinol group versus 19/757 in febuxostat 40 mg daily group, RR 1.63, 95% CI 0.93 to 2.87) (<a href="./references#CD006077-fig-0014" title="">Analysis 3.5</a>). Based on three trials, there were no between‐group differences in SAE comparing allopurinol and febuxostat 80 mg daily (SAEs: 57/1277 in allopurinol group versus 50/1279 in febuxostat 80 mg daily group, RR 1.13, 95% CI 0.71 to 1.82) (<a href="./references#CD006077-fig-0014" title="">Analysis 3.5</a>) (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and based on two trials, there were no between‐group differences in SAE comparing allopurinol with febuxostat 120 mg daily (SEAs: 26/521 in allopurinol group versus 30/520 in febuxostat 120 mg daily group, RR 0.86, 95% CI 0.52 to 1.44) (<a href="./references#CD006077-fig-0014" title="">Analysis 3.5</a>) (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a> reported no between‐group differences in SAE comparing allopurinol with febuxostat 240 mg daily (SAEs: 7/268 in allopurinol group versus 5/134 in febuxostat 240 mg daily group, RR 0.70, 95% CI 0.23 to 2.16) (<a href="./references#CD006077-fig-0014" title="">Analysis 3.5</a>). SAEs included non‐specific bacterial infections, coronary artery disease, lower respiratory tract infections, prostate cancer and death. </p> <p>There were nine deaths (six with febuxostat and three with allopurinol), all reported to be unrelated to the study drugs, in two trials (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>). </p> </section> <section id="CD006077-sec-0080"> <h4 class="title">Allopurinol versus benzbromarone</h4> <p>We considered data from two trials that compared allopurinol with benzbromarone to be sufficiently clinically homogeneous to be pooled (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999;</a><a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>). One trial that included 37 participants, judged to be at high risk of bias, compared allopurinol (100‐150 mg daily initially, titrated to 100, 200 or 300 mg daily according to creatinine clearance) with benzbromarone (100 mg daily titrated with increments of 50 mg daily to 200 mg daily) (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>). The trialists reported no between‐group difference in the number of acute gout attacks but did not provide data by treatment group. The second trial that included 65 participants, judged to be at unclear risk of bias, reported no between‐group difference in the frequency of acute gout attacks at four months (attacks: 0/30 in allopurinol group versus 1/25 in benzbromarone group, RR 0.28, 95% CI 0.01 to 6.58) (<a href="./references#CD006077-fig-0015" title="">Analysis 4.1</a>) (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>). </p> <p>Pooled analysis from the two studies of allopurinol and benzbromarone (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>: target 6 mg/dL or less, nine months; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>: target 5 mg/dL or less, four months) showed there was no between‐group difference with respect to the percentage of participants achieving the target serum urate (33/55 in allopurinol group versus 34/46 in benzbromarone group; pooled RR 0.79, 95% CI 0.56 to 1.11) (<a href="./references#CD006077-fig-0016" title="">Analysis 4.2</a>). No data for our other pre‐specified efficacy outcomes were reported in either trial (and tophi regression was not reported by treatment group in <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>). </p> <p>Pooled analysis of withdrawal due to AEs showed no between‐group difference between allopurinol and benzbromarone (3/49 in allopurinol group versus 3/42 in benzbromarone group, RR 0.85, 95% CI 0.21 to 3.52) (<a href="./references#CD006077-fig-0017" title="">Analysis 4.3</a>). Three participants in the allopurinol group withdrew due to skin rashes, while one participant in the benzbromarone group withdrew with dizziness and flushing and another two withdrew after gastrointestinal reactions. One additional person treated with benzbromarone was temporarily taken off of treatment when he developed diarrhoea and was not included in this analysis as benzbromarone was successfully re‐started and the AE was determined to be a result of colchicine (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>). </p> <p>In the trial by <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>, there was no between‐group difference in the number of participants with AEs (2/30 in allopurinol group versus 5/25 in benzbromarone group, RR 0.33, 95% CI 0.07 to 1.57) (<a href="./references#CD006077-fig-0018" title="">Analysis 4.4</a>). Two participants in the allopurinol group experienced rash/skin reactions and five participants in the benzbromarone group experienced adverse effects (two with gastrointestinal symptoms, one with an acute gout attack, one with dizziness and flushing, and one with an increase in international normalised ratio) and none was considered serious. In the trial by <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>, one participant died of cardiac failure three months after entering study, and the cause of death was considered to be unrelated to the study medication (and the medication was not specified). </p> </section> <section id="CD006077-sec-0081"> <h4 class="title">Allopurinol: intermittent versus continuous</h4> <p>One trial by <a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a> including 50 participants, judged to be at high risk of bias, compared two different allopurinol regimens. They reported no between‐group difference in the number of acute gout attacks between participants who received continuous allopurinol (allopurinol 100 mg daily for the first week, 200 mg daily for the second week and then maintained continuously by a dose adequate to keep their sUA level less than 6 mg/dL; this dose was usually 300 mg daily) and participants who received intermittent allopurinol (allopurinol starting at 100 mg daily for the first week, then 200 mg daily for the second week and then 300 mg daily for six weeks; this protocol could only be performed once every 12 months) during the first year. Thereafter, attacks occurred with reduced frequency in the continuous group compared with the intermittent group (attacks: 0/166 in continuous group versus 10/140 in intermittent group, RR 0.04, 95% CI 0.00 to 0.68) (<a href="./references#CD006077-fig-0019" title="">Analysis 5.1</a>). No data for joint pain, function, quality of life, participant global assessment of treatment success, tophus regression or harms were provided. </p> </section> <section id="CD006077-sec-0082"> <h4 class="title">Allopurinol: split‐dose versus once‐daily allopurinol</h4> <p>One cross‐over trial by <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a> including 20 participants, judged to be at high risk of bias, found no between‐group difference in number of participants who achieved a serum urate less than 6 mg/dL after two weeks of either allopurinol 300 mg daily or 100 mg three times daily (data not shown). </p> </section> <section id="CD006077-sec-0083"> <h4 class="title">Further safety assessment of allopurinol</h4> <p>From the UK MHRA pharmacovigilance and drug safety updates (<a href="http://www.mhra.gov.uk" target="_blank">www.mhra.gov.uk</a>) (accessed 15 January 2014), there were no new drug safety updates with allopurinol.  </p> <p>A search of the EMEA (<a href="http://www.emea.europa.eu" target="_blank">www.emea.europa.eu</a>) and Australian Adverse Drug Reactions Bulletin (<a href="http://www.tga.gov.au/adr/aadrb.htm" target="_blank">www.tga.gov.au/adr/aadrb.htm</a>) (accessed 15 January 2014), found no reports of SAEs of allopurinol, but did note the potential drug interactions of allopurinol with azathioprine, suggesting avoidance of their use together. The Adverse Drug Reactions Advisory Committee (ADRAC) received 10 reports (since 1980) attributing adverse haematological consequences to this interaction, including one report of a person who died.  </p> <p>Reports from a search of the US FDA MedWatch (<a href="http://www.fda.gov/Safety/MedWatch/default.htm" target="_blank">www.fda.gov/Safety/MedWatch/default.htm</a>) (accessed 15 January 2014), reported the incidence of adverse reactions with allopurinol is less than 1%. They reported the most common adverse reaction to allopurinol was skin rash, and recommended treatment be discontinued immediately if a rash develops. In some cases, a skin rash may be followed by more severe hypersensitivity reactions such as exfoliative, urticarial and purpuric lesions as well as Stevens‐Johnson syndrome (erythema multiforme exudativum) with or without generalised vasculitis.  </p> <p>An oral desensitisation regimen can be used in people with maculopapular rashes, particularly in people with gout who cannot be treated with uricosurics or other urate‐lowering drugs. <a href="./references#CD006077-bbs2-0056" title="FamAG , DunneSM , IazzettaJ , PatonTW . Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis and Rheumatism2001;44(1):231‐8. ">Fam 2001</a> performed a retrospective evaluation of an oral desensitisation regimen using gradual dosage‐escalation of allopurinol in 32 participants (30 with gout and two with chronic lymphocytic leukaemia) whose treatment was interrupted because of a pruritic cutaneous reaction to the drug. They reported that although pruritic skin eruptions may recur both during and after desensitisation, most of these cutaneous reactions could be managed by temporary withdrawal of allopurinol and dosage adjustment. </p> <p>The FDA reported on a few cases of reversible clinical hepatotoxicity in people taking allopurinol, and in some people, asymptomatic rises in serum alkaline phosphatase or transaminase have been observed. In people with pre‐existing liver disease, periodic liver function tests are recommended during the early stages of treatment with allopurinol. </p> <p>In cases where allopurinol (300 to 600 mg daily) is administered with mercaptopurine or azathioprine, a reduction in dose to approximately one‐third to one‐quarter of the usual dose of mercaptopurine or azathioprine should be made, and subsequent dose adjustment made on the basis of therapeutic response and the appearance of toxic effects. The FDA also reported that allopurinol can cause rare irreversible hepatotoxicity and, on occasions, death. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006077-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006077-sec-0084"></div> <section id="CD006077-sec-0085"> <h3 class="title" id="CD006077-sec-0085">Summary of main results</h3> <p>This systematic review analysed the evidence from all published RCT and CCTs of allopurinol in the treatment of chronic gout. We retrieved 11 trials including 4531 participants with chronic gout receiving allopurinol. There were seven RCTs (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>; <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>), and four CCTs (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>; <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>; <a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). Only one trial was at low risk of bias (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>), four at unclear risk of bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and six trials at high risk of bias (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>; <a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>; <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>; <a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). </p> <p>There was moderate‐quality evidence based on one trial (57 participants) of no between‐group difference in the rate of new or recurrent gout attacks when allopurinol 300 mg daily was compared with placebo, over a 30‐day period, and no between‐group difference in reduction of pain when allopurinol was compared with placebo over a 10‐day period (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). The trial was the first RCT to our knowledge, that compared allopurinol initiation during an acute attack of gout to delayed initiation (day 11) and has shown no difference in the rate of gout attacks or reduction in pain. There was moderate‐quality evidence based on this trial of a significant difference in the proportion of participants achieving a target serum urate level, favouring allopurinol 300 mg daily when compared with placebo over a 30‐day period. The NNTB was 1 (95% CI 1.04 to 1.35). There was moderate‐quality evidence based on the pooled data of two trials (453 participants) of no between‐group difference in the number of participants who withdrew due to AEs or in the number of participants who had SAEs, when allopurinol was compared with placebo over a 28‐week period (<a href="./full#CD006077-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>There was low‐quality evidence based on one small trial (65 participants) of no between‐group difference in the incidence of acute gout attacks, when allopurinol up to 300 mg twice daily was compared with benzbromarone up to 200 mg daily over a four‐month period. Based on the pooled results of two small trials (102 participants), there was moderate‐quality evidence of no between‐group difference in the proportion of participants achieving a target serum urate level and low‐quality evidence of no between‐group difference in the number of participants who withdrew due to AEs when allopurinol was compared with benzbromarone, over a four‐ to nine‐month period (<a href="./full#CD006077-tbl-0003">summary of findings Table 3</a>). In view of the small number of participants in these trials, they may have failed to detect a significant difference in these outcomes if one was truly present. </p> <p>There was low‐quality evidence based on pooled data from three trials (1136 participants) of no between‐group difference in the incidence of acute gout attacks when allopurinol up to 300 mg daily was compared with febuxostat 80 mg daily over an eight‐week period, during which co‐administration of flare prophylaxis with naproxen or colchicine was given in two trials (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and up to a 24‐week period (six months) in the third trial (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), which did not provide flare prophylaxis. There was low‐quality evidence based on pooled data of four trials (2618 participants) of a significant difference in the proportion of participants achieving target serum urate level favouring febuxostat 80 mg daily (RR 0.56, 95% CI 0.48 to 0.65; NNTH 4, 95% CI 3 to 5) as the intervention (allopurinol) was less effective at achieving target sUA than the comparator (febuxostat). There was moderate‐quality evidence based on the pooled data from three trials (2555 participants) of no between‐group difference in the number of participants who withdrew due to AEs of allopurinol up to 300 mg daily versus febuxostat 80 mg daily (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). There was also moderate‐quality evidence based on pooled data from these three trials (2556 participants) of no between‐group difference in the number of participants with SAEs when allopurinol up to 300 mg daily was compared with febuxostat 80 mg daily over a 24‐ to 52‐week period (<a href="./full#CD006077-tbl-0002">summary of findings Table 2</a>). One trial at unclear risk of bias showed no between‐group difference in the percentage reduction in tophus area at 52 weeks with 50% for participants on allopurinol 200 or 300 mg daily and 83% for participants on febuxostat 80 mg daily (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>). </p> <p>A further safety assessment on allopurinol was performed by searching the safety registries including the UK MHRA pharmacovigilance and drug safety updates (<a href="http://www.mhra.gov.uk" target="_blank">www.mhra.gov.uk</a>), EMEA (<a href="http://www.emea.europa.eu" target="_blank">www.emea.europa.eu</a>), Australian Adverse Drug Reactions Bulletin (<a href="http://www.tga.gov.au/adr/aadrb.htm" target="_blank">www.tga.gov.au/adr/aadrb.htm</a>) and the US FDA ‐ MedWatch (<a href="http://www.fda.gov/Safety/MedWatch/default.htm" target="_blank">www.fda.gov/Safety/MedWatch/default.htm</a>). The FDA reported the incidence of adverse reactions was less than 1%, and that the most common adverse reaction to allopurinol is skin rash, recommending treatment be discontinued immediately if a rash develops. In some cases, a skin rash may be followed by more severe hypersensitivity reactions such as exfoliative, urticarial and purpuric lesions as well as Stevens‐Johnson syndrome (erythema multiforme exudativum) or generalised vasculitis or both. </p> </section> <section id="CD006077-sec-0086"> <h3 class="title" id="CD006077-sec-0086">Overall completeness and applicability of evidence</h3> <p>We have included 11 published trials (seven RCTs and four CCTs) examining the efficacy and safety of allopurinol in the treatment of chronic gout. Two studies assessed allopurinol versus placebo (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008;</a><a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>), two studies assessed allopurinol versus benzbromarone (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>), while three RCTs and one CCT examined allopurinol versus febuxostat (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>; <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>). We summarised these studies in the 'Summary of findings' tables as the most clinically relevant comparisons. </p> <p>The remaining four trials compared allopurinol with other treatments. One RCT compared allopurinol 200 mg daily plus colchicine 0.5 mg twice daily with colchicine 0.5 mg twice daily alone (<a href="./references#CD006077-bbs2-0004" title="GibsonT , RodgersV , PotterC , SimmondsHA . Allopurinol treatment and its effect on renal function in gout: a controlled study. Annals of the Rheumatic Diseases1982;41(1):59‐65. ">Gibson 1982</a>). One open quasi‐randomised CCT compared allopurinol 300 to 600 mg daily to probenecid 1 g daily increasing to 2 g daily after two weeks (<a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>). One quasi‐randomised CCT compared two different allopurinol regimens (continuous versus intermittent) (<a href="./references#CD006077-bbs2-0003" title="BullPW , ScottJT . Intermittent control of hyperuricemia in the treatment of gout. Journal of Rheumatology1989;16(9):1246‐48. ">Bull 1989</a>). One open cross‐over CCT compared allopurinol 300 mg daily with allopurinol 100 mg three times daily (<a href="./references#CD006077-bbs2-0007" title="RodnanGP , RobinJA , TolchinSF , ElionGB . Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA1975;231(11):1143‐7. ">Rodnan 1975</a>). </p> <p>Based on the inclusion criteria of these 11 trials (<a href="./references#CD006077-sec-0114" title="">Characteristics of included studies</a>), the results are most relevant to males, aged 50 to 60 years without any significant renal or liver disease. As benzbromarone is not currently available in many countries, there is also a limitation to the applicability of the allopurinol versus benzbromarone data to current practice. However, allopurinol and febuxostat are widely available for use in clinical practice. </p> </section> <section id="CD006077-sec-0087"> <h3 class="title" id="CD006077-sec-0087">Quality of the evidence</h3> <p>There was a paucity of high‐quality RCTs comparing allopurinol versus placebo, with only two trials assessing this comparison. As there was significant clinical heterogeneity between these trials, we could not pool their efficacy data. One trial judged to be at low risk of bias and of small size (57 participants) was designed to test the hypothesis that there is no difference in pain or the frequency of gout attacks with early versus delayed initiation of allopurinol for an acute attack of gout (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). In doing this, the participants received allopurinol versus placebo for a short 10‐day period only (and the total trial duration was 90 days, as colchicine was continued for 90 days). It was the only trial that assessed pain as an outcome, and confirmed the hypothesis relating to pain and acute gout attack frequency over a short period of 10 days. In comparison, another trial was judged to be at unclear risk of bias; however, it was much larger (1072 participants) and had a longer (28 week) duration of follow‐up (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). There was moderate‐quality evidence based on these two trials that allopurinol 100 to 300 mg daily probably does not reduce the number of acute gout attacks or pain, but does increase the proportion achieving target serum urate levels compared with placebo, without increasing withdrawals due to AEs or SAE rates. Further research may change the estimates. There was low‐quality evidence that there may be no difference in pain reduction when allopurinol was compared with placebo over a 10‐day period (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>), and no difference in tophus regression (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). However, limited data were reported so further research is likely to change the estimates. Neither trial included an assessment of function or participant global assessment of treatment success. </p> <p>There was also a paucity of high‐quality RCTs comparing allopurinol versus benzbromarone, and we only identified two trials assessing this comparison (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999;</a><a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>). These trials were limited by their small size (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>: 65 participants; <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>: 36 participants). In addition, the study by <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a> was limited by the short duration (four months) while the <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a> trial had limitations related to the variable duration of follow‐up. Neither trial included a placebo arm and both trials were open‐label rendering them at risk of performance and detection bias. As both of the allopurinol versus benzbromarone trials were small, there was a risk that they lacked power to detect differences in the outcomes discussed. There was low‐quality evidence based on these two trials that allopurinol up to 600 mg daily may not reduce the number of acute gout attacks, and moderate‐quality evidence that allopurinol up to 600 mg daily may not increase the proportion of participants achieving target serum urate levels compared with benzbromarone up to 200 mg daily. There may be no difference in the number of withdrawals due to AEs or SAE rates. Further research may change the estimates. Tophus regression was not fully reported and pain, function and participant global assessment of treatment success were not measured. </p> <p>There was low‐quality evidence from three RCTs (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and one CCT (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), comparing allopurinol up to 300 mg daily versus febuxostat 80 mg daily, that allopurinol 100 to 300 mg daily may not reduce the number of acute gout attacks, and may be less effective in achieving target serum urate levels compared with febuxostat 80 mg daily, without increasing withdrawals due to AEs or SAE rates. Three studies were at unclear risk (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>; <a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>) and one study at high risk (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>) of performance and detection bias. One trial was at high risk of attrition bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>), whereas one trial was at unclear risk of attrition bias (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), and the other two studies were at low risk of attrition bias (<a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>; <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), therefore reducing the overall quality of the evidence. Furthermore, three studies used low dose allopurinol 100 to 300 mg daily (depending on renal function) compared with a reasonable dose of febuxostat 80 mg daily (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). There was low‐quality evidence that there may be no difference in tophus regression between allopurinol up to 300 mg daily and febuxostat 80 mg daily. Further research is likely to change the estimates. None of these trials included an assessment of pain, function or participant global assessment of treatment success. </p> <p>None of the trials appeared to be limited by indirectness or inconsistency of results. In addition, there did not appear to be a high risk of publication bias. </p> <p>All other comparisons were supported by small, single studies only, limiting conclusions.</p> </section> <section id="CD006077-sec-0088"> <h3 class="title" id="CD006077-sec-0088">Potential biases in the review process</h3> <p>We are confident that the broad literature search used in this review has captured all relevant studies. Two review author independently performed a review of all abstracts and titles as well as data extraction and risk of bias assessment. Consensus was reached after discussing any discrepancies thus minimising bias. We performed a sensitivity analysis where there was concern about risk of bias of an included non‐randomised CCT, and this showed no overall difference. The biggest limitation of the review process was the heterogeneity between the trials and the lack of data in a form that could be extracted for meta‐analysis. To address more SAEs, we also searched regulatory agency reports. </p> </section> <section id="CD006077-sec-0089"> <h3 class="title" id="CD006077-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>Current guidelines by the British Society for Rheumatology (<a href="./references#CD006077-bbs2-0064" title="JordanKM , CameronJS , SnaithM , ZhangW , DohertyM , SecklJ . British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology2007;46(8):1372‐4. ">Jordan 2007</a>), ACR (<a href="./references#CD006077-bbs2-0066" title="KhannaD , FitzgeraldJD , KhannaPP , BaeS , SinghMK , NeogiT , et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Research2012;64(10):1431‐46. ">Khanna 2012</a>), and EULAR (<a href="./references#CD006077-bbs2-0079" title="ZhangW , DohertyM , BardinT , PascualE , BarskovaV , ConaghanP , et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases2006;65:1312‐24. ">Zhang 2006</a>), recommendations by <a href="./references#CD006077-bbs2-0059" title="HamburgerM , BarafHS , AdamsonTC3rd , BasileJ , BassL , ColeB , et al. Recommendations for the diagnosis and management of gout and hyperuricaemia. Postgraduate Medicine2011;163(6):3‐36. ">Hamburger 2011</a>, and the FDA all recommend starting allopurinol at a low dose of 100 mg daily and increasing the dose slowly, every two to five weeks. Our review identified trials where allopurinol doses ranged from 100 to 600 mg daily and highlighted one moderate‐quality RCT where a dose of 300 mg daily of allopurinol was compared with placebo and is the first to our knowledge that compared allopurinol initiation during an acute attack of gout to delayed initiation (day 11) and demonstrated no difference in the rate of gout attacks or reduction in pain (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). These findings may begin to change our current clinical practice from delaying the initiation of urate‐lowering therapy until after the acute attack has settled, to starting urate‐lowering treatment during an acute attack of gout. The ACR gout guidelines suggest that urate‐lowering therapy could be started during an acute gout attack, providing that effective acute management is instituted, and these recommendations are based on "consensus opinion of experts, case studies, or standard of care", rather than RCT evidence, as we have shown (<a href="./references#CD006077-bbs2-0066" title="KhannaD , FitzgeraldJD , KhannaPP , BaeS , SinghMK , NeogiT , et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Research2012;64(10):1431‐46. ">Khanna 2012</a>). While the <a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a> trial was published in November 2012, after the ACR guidelines were published, it does support ACR recommendations although it may be underpowered (as it is a small trial with 57 participants) and was of short duration. Therefore, further high‐quality RCT evidence assessing early versus delayed initiation of urate lowering therapy would be useful. </p> <p>The ACR recommends gradual upwards titration of the allopurinol dose every two to five weeks to an appropriate maximum dose for gout, in order to treat to the serum urate target appropriate for the individual participant. The FDA dosing guide lists 200 to 300 mg daily as typical doses for people with mild gout and doses of 400 to 600 mg daily for people with moderately severe tophaceous gout. Allopurinol can be used at doses as high as 800 mg daily to achieve target serum urate level less than 6.0 mg/dL (less than 0.36 mmol/L), although limited safety data were available at these high doses (<a href="./references#CD006077-bbs2-0051" title="ChaoJ , TerkeltaubR . A critical reappraisal of allopurinol dosing, safety and efficacy for hyperuricaemia in gout. Current Rheumatology Reports2009;11(2):135‐40. ">Chao 2009</a><a href="./references#CD006077-bbs2-0059" title="HamburgerM , BarafHS , AdamsonTC3rd , BasileJ , BassL , ColeB , et al. Recommendations for the diagnosis and management of gout and hyperuricaemia. Postgraduate Medicine2011;163(6):3‐36. ">Hamburger 2011</a>). Our review did not identify any RCTs or CCTs that used allopurinol in doses as high as 800 mg daily, although one trial titrated the dose to 600 mg daily, which enabled achievement of the target serum urate target level (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>). </p> <p>Our review did not identify any RCTs that compared allopurinol with probenecid in chronic gout, although did retrieve one CCT at high risk of bias where limited data were presented (<a href="./references#CD006077-bbs2-0009" title="ScottJT . Comparison of allopurinol and probenecid. Annals of the Rheumatic Diseases1966;25(6 Suppl):623‐6. ">Scott 1966</a>). The EULAR guidelines (<a href="./references#CD006077-bbs2-0079" title="ZhangW , DohertyM , BardinT , PascualE , BarskovaV , ConaghanP , et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases2006;65:1312‐24. ">Zhang 2006</a>) and gout recommendations by <a href="./references#CD006077-bbs2-0059" title="HamburgerM , BarafHS , AdamsonTC3rd , BasileJ , BassL , ColeB , et al. Recommendations for the diagnosis and management of gout and hyperuricaemia. Postgraduate Medicine2011;163(6):3‐36. ">Hamburger 2011</a> suggest a role for probenecid, a uricosuric agent, as an alternative to allopurinol, based on data from uncontrolled trials (e.g. <a href="./references#CD006077-bbs2-0038" title="ReindersM , vanRoonE , HoutmanP , BrouwersJ , JansenT . Biochemical effectiveness of allopurinol and allopurinol‐probenecid in previously benzbromarone‐treated gout patients. Clinical Rheumatology2007;26(9):1459‐65. ">Reinders 2007;</a><a href="./references#CD006077-bbs2-0043" title="StockerSL , GrahamGG , McLachlanAJ , WilliamsKM , DayRO . Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. Journal of Rheumatology2011;38(5):904‐10. ">Stocker 2011</a>), which we excluded. </p> <p>In contrast to our review that separately compared allopurinol 100 to 300 mg daily with different doses of febuxostat (40, 80, 120 and 240 mg daily), one systematic review pooled data comparing allopurinol 100 to 300 mg daily with different daily doses of febuxostat (40, 80, 120 and 240 mg daily) into a single meta‐analysis (<a href="./references#CD006077-bbs2-0057" title="FaruqueLI , Ehteshami‐AfsharA , WiebeN , TjosvoldL , HomikJ , TonelliM . A systematic review and meta‐analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Seminars in Arthritis and Rheumatism2013;43:367‐75. ">Faruque 2013</a>). They reported that participants on febuxostat (all doses combined) were more likely to have a gout attack when compared with allopurinol 100 to 300 mg daily (RR 1.16, 95% CI 1.02 to 1.31), and more likely to achieve target serum urate level (RR 1.56, 95% CI 1.22 to 2.0). This is consistent with our results comparing allopurinol with febuxostat 120 and 240 mg for acute gout attacks and our results comparing allopurinol with febuxostat 80, 120 and 240 mg for achieving the target serum urate. However, we found no between‐group differences between allopurinol up to 300 mg daily and febuxostat 80 mg daily with respect to acute gout attacks and no between‐group differences between allopurinol 200 or 300 mg daily and febuxostat 40 mg daily with respect to serum urate normalisation. Both reviews reported similar safety data. </p> <p>In contrast to our review, <a href="./references#CD006077-bbs2-0057" title="FaruqueLI , Ehteshami‐AfsharA , WiebeN , TjosvoldL , HomikJ , TonelliM . A systematic review and meta‐analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Seminars in Arthritis and Rheumatism2013;43:367‐75. ">Faruque 2013</a> included two trials with mixed populations of people with hyperuricaemia and chronic gout (<a href="./references#CD006077-bbs2-0024" title="KamataniN , FujimoriS , HadaT , HosoyaT , KohriK , ToshitakaN , et al. An allopurinol‐controlled, multicenter, randomized, open‐label, parallel between‐group, comparative study of febuxostat (TMX‐67), a non‐purine‐selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. Journal of Clinical Rheumatology2011;17(4 Suppl 2):S44‐9. ">Kamatani 2011a</a> (S13‐18); <a href="./references#CD006077-bbs2-0025" title="KamataniN , FujimoriS , HadaT , HosoyaT , KohriK , NakamuraT , et al. An allopurinol‐controlled, randomized, double‐dummy, double‐blind, parallel between‐group, comparative study of febuxostat (TMX‐67), a non‐purine‐selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. Journal of Clinical Rheumatology2011;17(4 Suppl 2):S13‐8. ">Kamatani 2011b</a> (S44‐S49); and excluded <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a> from their review due to methodological limitations. While we recognised that <a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a> was at high risk of bias, a sensitivity analysis excluding this trial did not alter our results for acute gout attack frequency, proportion of participants achieving target serum urate and total AEs. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006077-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006077-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006077-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006077-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Allopurinol versus placebo, Outcome 1 Acute gout attacks." data-id="CD006077-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Allopurinol versus placebo, Outcome 1 Acute gout attacks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Allopurinol versus placebo, Outcome 2 Proportion achieving target serum urate." data-id="CD006077-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Allopurinol versus placebo, Outcome 2 Proportion achieving target serum urate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Allopurinol versus placebo, Outcome 3 Withdrawal due to adverse events." data-id="CD006077-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Allopurinol versus placebo, Outcome 3 Withdrawal due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Allopurinol versus placebo, Outcome 4 Total adverse events." data-id="CD006077-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Allopurinol versus placebo, Outcome 4 Total adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Allopurinol versus placebo, Outcome 5 Serious adverse events." data-id="CD006077-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Allopurinol versus placebo, Outcome 5 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Allopurinol plus colchicine versus colchicine alone, Outcome 1 Acute gout attack frequency." data-id="CD006077-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Allopurinol plus colchicine versus colchicine alone, Outcome 1 Acute gout attack frequency. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Allopurinol versus febuxostat, Outcome 1 Acute gout attacks." data-id="CD006077-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Allopurinol versus febuxostat, Outcome 1 Acute gout attacks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Allopurinol versus febuxostat, Outcome 2 Proportion achieving target serum urate (6‐12 months)." data-id="CD006077-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Allopurinol versus febuxostat, Outcome 2 Proportion achieving target serum urate (6‐12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Allopurinol versus febuxostat, Outcome 3 Withdrawals due to adverse events." data-id="CD006077-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Allopurinol versus febuxostat, Outcome 3 Withdrawals due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Allopurinol versus febuxostat, Outcome 4 Total adverse events." data-id="CD006077-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Allopurinol versus febuxostat, Outcome 4 Total adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Allopurinol versus febuxostat, Outcome 5 Serious adverse events." data-id="CD006077-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Allopurinol versus febuxostat, Outcome 5 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Allopurinol versus benzbromarone, Outcome 1 Acute gout attacks." data-id="CD006077-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Allopurinol versus benzbromarone, Outcome 1 Acute gout attacks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Allopurinol versus benzbromarone, Outcome 2 Proportion achieving target serum urate." data-id="CD006077-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Allopurinol versus benzbromarone, Outcome 2 Proportion achieving target serum urate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Allopurinol versus benzbromarone, Outcome 3 Withdrawal due to adverse events." data-id="CD006077-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Allopurinol versus benzbromarone, Outcome 3 Withdrawal due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Allopurinol versus benzbromarone, Outcome 4 Total adverse effects." data-id="CD006077-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Allopurinol versus benzbromarone, Outcome 4 Total adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006077-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/urn:x-wiley:14651858:media:CD006077:CD006077-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_t/tCD006077-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Allopurinol: continuous versus intermittent, Outcome 1 Acute gout attacks." data-id="CD006077-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Allopurinol: continuous versus intermittent, Outcome 1 Acute gout attacks.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/media/CDSR/CD006077/image_n/nCD006077-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006077-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Allopurinol compared with placebo for chronic gout</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Allopurinol compared with placebo for chronic gout</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with chronic gout<br/> <b>Settings:</b> primary care<br/> <b>Intervention:</b> allopurinol 100‐300 mg daily<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Allopurinol</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute gout attacks</b> <br/> Follow‐up: 1‐30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> <br/> (14 to 422) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.64</b> <br/> (0.12 to 3.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute reduction in attacks with allopurinol: 4% (21% reduction to 12% increase)</p> <p>Relative change: 36% reduction with allopurinol (88% reduction to 252% increase)</p> <p>NNTB n/a<sup>2</sup> </p> <p>This study used allopurinol 300 mg daily (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion achieving target serum urate</b> <br/> Follow‐up: 1‐30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>960 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>960 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 49.11</b> <br/> (3.15 to 765.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference in proportion achieving target serum urate with allopurinol: 96% (86% to 106% increase) </p> <p>Relative change: 48% increase with allopurinol (215% to 76,458% increase)</p> <p>NNT 1 (95% CI 1.04 to 1.35)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain reduction</b> <br/> Follow‐up: 10 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors reported no difference in pain: the initial mean VAS pain scores for the allopurinol and placebo groups were 6.72 versus 6.28 (P value = 0.37) decreasing to 0.18 versus 0.27 (P value = 0.54) at day 10. No measures of variance reported, so we could not calculate the differences between groups<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tophus regression</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal due to adverse events</b> <br/> Follow‐up: 0‐28 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>60 per 1000</b> <br/> (26 to 136) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.36</b> <br/> (0.61 to 3.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>453<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk difference in withdrawals due to adverse events with allopurinol: 2% increase (3% reduction to 6% increase) </p> <p>Relative change: 37% increase with allopurinol (39% reduction to 209% increase)</p> <p>NNT n/a<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> <br/> Follow‐up: 0‐28 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>13 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>24 per 1000</b> <br/> (6 to 98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.93</b> <br/> (0.48 to 7.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>453<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk difference in serious adverse events with allopurinol: 1% increase (1% reduction to 4% increase) </p> <p>Relative change: 93% increase with allopurinol (52% reduction to 676% increase)</p> <p>NNT n/a<sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>VAS:</b> visual analogue scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> One study with a small sample size, and wide CIs, indicating imprecision (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). </p> <p><sup>2</sup> Number needed to treat for an additional beneficial outcome (NNTB) or harmful outcome (NNTH) not applicable (n/a) when result was not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (<a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx/</a>).<br/> <sup>3</sup> Data from two studies were pooled for withdrawal due to adverse events and serious adverse events, the earlier trial is at unclear risk of selection, performance and detection bias, and the more recent trial is at low risk of bias (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008;</a><a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>).<br/> <sup>4</sup> One study reported on pain reduction, and is at low risk of bias, and had a small sample size (<a href="./references#CD006077-bbs2-0011" title="TaylorTH , MecchellaJN , LarsonRJ , KerinKD , MackenzieTA . Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. American Journal of Medicine2012;125(11):1126‐34. ">Taylor 2012</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Allopurinol compared with placebo for chronic gout</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006077-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Allopurinol 100‐300 mg daily compared with febuxostat 80 mg daily for chronic gout</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Allopurinol 100‐300 mg daily compared with febuxostat 80 mg daily for chronic gout</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with chronic gout<br/> <b>Settings: p</b> rimary and secondary care<br/> <b>Intervention:</b> allopurinol 100‐300 mg daily<br/> <b>Comparison: f</b>ebuxostat 80 mg daily </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Febuxostat 80 mg daily</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Allopurinol 100‐300 mg daily</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute gout attacks</b> <br/> Follow‐up: up to 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>233 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>207 per 1000</b> <br/> (165 to 256) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.89</b> <br/> (0.71 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1136<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute reduction in attacks with allopurinol: 2% (7% reduction to 3% increase)</p> <p>Relative change: 11% reduction with allopurinol (29% reduction to 10% increase)</p> <p>Not statistically significant. NNT n/a<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion achieving target serum urate</b> <br/> Follow‐up: 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>697 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>383 per 1000</b> <br/> (335 to 439) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.56</b> <br/> (0.48 to 0.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2618<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference in proportion achieving target serum urate with allopurinol: 32% fewer with allopurinol (40% fewer to 25% fewer) </p> <p>Relative change: 45% fewer with allopurinol (52% reduction to 37% reduction).</p> <p>NNTH 4 (95% CI 3 to 5)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain reduction</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tophus regression</b> <br/> Follow‐up: 52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were no between‐group difference in the percentage reduction in tophus area at 52 weeks with 50% for participants taking allopurinol 200 or 300 mg daily and 83% for participants taking febuxostat 80 mg daily (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal due to adverse effects</b> <br/> Follow‐up: 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>68 per 1000</b> <br/> (48 to 97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.89</b> <br/> (0.62 to 1.26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2555<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk difference in withdrawals due to adverse events with allopurinol: 1% reduction with allopurinol (3% reduction to 1% increase) </p> <p>Relative change: 11% reduction with allopurinol (38% reduction to 26% increase).</p> <p>Not statistically significant. NNT n/a<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse effects</b> <br/> Follow‐up: 24‐52 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>39 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>44 per 1000</b> <br/> (28 to 71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.13</b> <br/> (0.71 to 1.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2556<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3,5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk difference in serious adverse events with allopurinol: 0% (2% reduction to 3% increase) </p> <p>Relative change: 13% increase with allopurinol (29% reduction to 82% increase)</p> <p>Not statistically significant. NNT n/a<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Two studies were at unclear risk (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and one study was at high risk (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), of performance and detection bias.<br/> <sup>2</sup> One study was at high risk of attrition bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>), one at unclear risk of attrition bias (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), and one at low risk of attrition bias (<a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>).<br/> <sup>3</sup> Three studies were at unclear risk (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>), and one study at high risk of performance and detection bias (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), and one trial at high risk of attrition bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005</a>), whereas one was at unclear risk of attrition bias (<a href="./references#CD006077-bbs2-0010" title="SingalKK , GoyalS , GuptaP , AggawalBK . Comparison between allopurinol and febuxostat in management of gout patients ‐ a prospective study. Bangladesh Journal of Medical Science2011;10:257‐9. ">Singal 2011</a>), and the other two studies were at low risk of attrition bias (<a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010</a>, <a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>).<br/> <sup>4</sup> Three studies used low‐dose allopurinol (100 to 300 mg daily depending on renal function) (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>).<br/> <sup>5</sup> Three studies were at unclear risk of reporting bias (<a href="./references#CD006077-bbs2-0001" title="BeckerMA , SchumacherHRJr , WortmannRL , MacDonaldPA , EustaceD , PaloWA , et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine2005;353(23):2450‐61. ">Becker 2005;</a><a href="./references#CD006077-bbs2-0002" title="BeckerMA , SchumacherHR , EspinozaLR , WellsAF , MacDonaldP , LloydE , et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research Therapy2010;12(2):R63. ">Becker 2010;</a><a href="./references#CD006077-bbs2-0008" title="SchumacherHR , BeckerMA , WortmannRL , MacdonaldPA , HuntB , StreitJ , et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis and Rheumatism2008;59(11):1540‐8. ">Schumacher 2008</a>). </p> <p><sup>6</sup> Number needed to treat for an additional beneficial outcome (NNTB) or harmful outcome (NNTH) not applicable (n/a) when result was not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (<a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx/</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Allopurinol 100‐300 mg daily compared with febuxostat 80 mg daily for chronic gout</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006077-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Allopurinol compared with benzbromarone for people with chronic gout</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Allopurinol compared with benzbromarone for people with chronic gout</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with chronic gout<br/> <b>Settings:</b> primary and secondary care<br/> <b>Intervention:</b> allopurinol 100‐600 mg daily<br/> <b>Comparison:</b> benzbromarone 100‐200 mg daily </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Benzbromarone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Allopurinol </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute gout attacks</b> <br/> Follow‐up: mean 4 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> <br/> (0 to 263) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.28</b> <br/> (0.01 to 6.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute reduction in attacks with allopurinol: 4% (14% reduction to 6% increase)</p> <p>Relative change: 72% reduction with allopurinol (99% reduction to 558% increase)</p> <p>Not statistically significant. NNT n/a<sup>4</sup> </p> <p>This study used allopurinol 100‐600 mg daily (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion achieving target serum urate</b> <br/> Follow‐up: 4‐9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>739 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>584 per 1000</b> <br/> (414 to 820) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.79</b> <br/> (0.56 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference in proportion achieving target serum urate with allopurinol: 17% reduction with allopurinol (45% reduction to 10% increase) </p> <p>Relative change: 21% reduction with allopurinol (44% reduction to 11% increase)</p> <p>Not statistically significant. NNT n/a<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain reduction</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> ‐ not measured </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tophus regression</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported in 1 study (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>), while the other study reported that 18/20 participants were cleared of tophi at 24 months but the authors do not provide further data for analysis) (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal due to adverse events</b> <br/> Follow‐up: median 4‐9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>57 per 1000</b> <br/> (13 to 256) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.80</b> <br/> (0.18 to 3.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk difference in withdrawals due to adverse events with allopurinol: 1% increase with allopurinol (10% reduction to 11% increase) </p> <p>Relative change: 20% reduction with allopurinol (82% reduction to 258% increase)</p> <p>Not statistically significant. NNT n/a<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse effects</b> <br/> Follow‐up: 4‐9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No adverse effects were considered serious" in the trial by <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a> and 1 participant died of cardiac failure after entering the <a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a> trial, and the cause of death was thought unrelated to the study medication (which was not specified) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Small study (65 participants) (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>). Few events resulting in wide confidence interval.<br/> <sup>2</sup> Open‐label study with possible performance and detection bias and unclear risk related to possible attrition bias (<a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>).<br/> <sup>3</sup> Open‐label studies with possible performance bias and unclear risk related to possible attrition bias (<a href="./references#CD006077-bbs2-0005" title="Perez‐RuizF , CalabozoM , Fernandez‐LopezMJ , Herrero‐BeitesA , Ruiz‐LuceaE , Garcia‐ErauskinG , et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. Journal of Clinical Rheumatology1999;5(2):49‐55. ">Perez‐Ruiz 1999</a>; <a href="./references#CD006077-bbs2-0006" title="ReindersMK , HaagsmaC , JansenTL , vanRoonEN , DelsingJ , van deLaarMA , et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300‐600 mg/day versus benzbromarone 100‐200 mg/day in patients with gout. Annals of the Rheumatic Diseases2009;68(6):892‐7. ">Reinders 2009a</a>). </p> <p><sup>4</sup> Number needed to treat for an additional beneficial outcome (NNTB) or harmful outcome (NNTH) not applicable (n/a) when result is not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (<a href="http://www.nntonline.net/visualrx/" target="_blank">www.nntonline.net/visualrx/</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Allopurinol compared with benzbromarone for people with chronic gout</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/full#CD006077-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006077-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Allopurinol versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acute gout attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion achieving target serum urate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.61, 3.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.48, 7.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Allopurinol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006077-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Allopurinol plus colchicine versus colchicine alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acute gout attack frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.25, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Allopurinol plus colchicine versus colchicine alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006077-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Allopurinol versus febuxostat</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acute gout attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Febuxostat 80 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.71, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Febuxostat 120 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.51, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Febuxostat 240 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.34, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion achieving target serum urate (6‐12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Febuxostat 40 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Febuxostat 80 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.48, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Febuxostat 120 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.42, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Febuxostat 240 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.36, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Febuxostat 40 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.92, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Febuxostat 80 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.62, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Febuxostat 120 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.56, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Febuxostat 240 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.35, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Febuxostat 40 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.93, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Febuxostat 80 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [1.01, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Febuxostat 120 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.05, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Febuxostat 240 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.90, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.85, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Febuxostat 40 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.93, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Febuxostat 80 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.71, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Febuxostat 120 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.52, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Febuxostat 240 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.7 [0.23, 2.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Allopurinol versus febuxostat</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006077-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Allopurinol versus benzbromarone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acute gout attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion achieving target serum urate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.56, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.18, 3.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.07, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Allopurinol versus benzbromarone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006077-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Allopurinol: continuous versus intermittent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acute gout attacks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Allopurinol: continuous versus intermittent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006077.pub3/references#CD006077-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006077.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006077-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006077-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006077-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD006077-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD006077-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD006077-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006077\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006077\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006077\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006077\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006077\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006077.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006077.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006077.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006077.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006077.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715140864"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006077.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715140868"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006077.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7fd7f97f1bde',t:'MTc0MDcxNTE0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 